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Abstract: 35 
Osteoporosis associated with long-term glucocorticoid therapy remains a common and serious bone 36 
disease. In addition, in recent years it has become clear that more subtle states of endogenous 37 
glucocorticoid excess may have a major impact on bone health. Adverse effects can be seen with 38 
mild systemic glucocorticoid excess but there is also evidence of tissue-specific regulation of 39 
glucocorticoid action within bone as a mechanism of disease. This review article will examine a) the 40 
role of endogenous glucocorticoids in normal bone physiology, b) the skeletal effects of endogenous 41 
glucocorticoid excess in the context of endocrine conditions such as Cushing’s disease and 42 
autonomous cortisol secretion (subclinical Cushing’s syndrome), and c) the actions of therapeutic 43 
(exogenous) glucocorticoids on bone. We will review the extent to which the effect of 44 
glucocorticoids on bone is influenced by variations in tissue metabolising enzymes and 45 
glucocorticoid receptor expression and sensitivity. We will consider how the effects of therapeutic 46 
glucocorticoids on bone are complicated by the effects of the underlying inflammatory disease being 47 
treated. We will also examine the impact that glucocorticoid replacement regimens have on bone in 48 
the context of primary and secondary adrenal insufficiency.  49 
 50 
Precis: 51 
We reviewed literature relating to the effects of glucocorticoids on bone. This included the impact of 52 
endogenously synthesised and therapeutically administered glucocorticoids on bone and bone cells. 53 
  54 
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I.  Introduction 55 
Glucocorticoid induced osteoporosis (GIOP) remains an important and common clinical problem. 56 
GIOP was first recognised in patients with Cushing’s disease or other states of endogenous 57 
glucocorticoid excess.1 However, since the introduction of therapeutic glucocorticoids over 60 years 58 
ago, GIOP is now much more commonly seen in people treated with therapeutic glucocorticoids.2 It 59 
is well established that therapeutic glucocorticoid treatment is associated with significant loss of 60 
bone density, deterioration of bone structure and substantial increases in fracture risk.3,4 The 61 
condition appears to behave in many ways distinct to that of age-related or postmenopausal 62 
osteoporosis and, as such, is regarded as a distinct metabolic bone disease.5  63 
The study of GIOP is complicated by the almost universal involvement of an underlying, usually 64 
inflammatory disease, as the reason for glucocorticoid treatment in the first place.5,6 These 65 
underlying illnesses are rarely incorporated into animal models examining the pathogenesis of GIOP. 66 
Various treatments have been evaluated for GIOP in the clinical setting but usually only after these 67 
have proven effective in the context of postmenopausal osteoporosis. Trials in GIOP are generally 68 
powered based on BMD changes rather than fracture risk reduction. All current treatments for GIOP 69 
have significant limitations in terms of effectiveness and risk of adverse effects.  70 
In addition to the clear evidence that high levels of therapeutic glucocorticoids do harm to bone 71 
there is increasing evidence that more subtle states of endogenous of glucocorticoid excess 72 
detrimentally impact on bone.7 The main focus of this research has been the impact of subclinical 73 
endogenous hypercortisolism (also known as sub-clinical Cushing’s syndrome or autonomous 74 
cortisol secretion), a condition characterised by autonomous cortisol secretion usually by one or 75 
more adrenal cortex nodules. There is current debate regarding how prevalent this condition is and 76 
how significant its impact is on bone but many studies indicate that the effects on bone can be 77 
substantial.7 It is less clear how to investigate and manage bone loss and extra-skeletal 78 
manifestations in subclinical endogenous hypercortisolism.  79 Comment [M1]: ? add graphical 
abstract here? 
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There is now considerable evidence that glucocorticoid action can be modulated by various 80 
mechanisms at a tissue level. These mechanisms include variations in the expression and sensitivity 81 
of the glucocorticoid receptors8, export of steroids out of the cell by transmembrane transporters9 82 
and enzymatic metabolism of glucocorticoids to more or less active forms.10 In particular, there has 83 
been interest in the role of the 11β-hydroxysteroid dehydrogenases (11β-HSDs) which interconvert 84 
the active glucocorticoids cortisol and corticosterone with their inactive counterparts cortisone and 85 
dehydrocorticosterone.10 These enzymes appear to influence bone cell differentiation and function 86 
and changes in enzyme expression have been implicated in the development of some aspects of 87 
glucocorticoid induced bone loss. Excessive tissue glucocorticoid action in the presence of normal 88 
circulating levels of glucocorticoids might thus play a more generalised role in other forms of 89 
osteoporosis not traditionally associated with glucocorticoid excess.  90 
The issue of whether glucocorticoid levels are sufficient, inadequate or excessive for bone health is 91 
relevant to the treatment of states of adrenal insufficiency such as Addison’s disease or 92 
hypopituitarism. Evidence suggests that historically, glucocorticoid replacement regimens were 93 
excessive in many people and this is likely to have detrimentally impacted on bone health. More 94 
contemporary (and lower) replacement glucocorticoid doses appear to have less of an adverse 95 
impact on bone in terms of bone density and biochemical markers. However, whether this translates 96 
into reduced fracture risk is unclear. 97 
This review will therefore examine the role endogenous glucocorticoids play in normal bone 98 
physiology, examine the skeletal effects of endogenous glucocorticoid excess in the context of 99 
endocrine conditions such as Cushing’s disease and autonomous cortisol secretion, and explore the 100 
actions of therapeutic glucocorticoids on bone. Based on a MedlineTM publication search within the 101 
last five years (to February 2018) supplemented by earlier studies of continuing significance we 102 
review how the effect of glucocorticoids on bone is influenced by tissue metabolising enzymes and 103 
glucocorticoid receptor expression. We will consider how these effects are complicated by 104 
Comment [RSH2]: Could use a figure 
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inflammation. We will additionally examine the impact that glucocorticoid replacement has on bone 105 
in the context of adrenal insufficiency.  106 
  107 
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II Mechanisms of action of glucocorticoids on bone 108 
This section outlines how glucocorticoids have their effect on bone. Evidence primarily based on 109 
mouse models suggests that the main adverse effects of high levels of glucocorticoids on bone are 110 
through direct effects on cells involved in bone remodelling; osteoblasts, osteocytes and osteoclasts. 111 
Mechanisms such as impaired cellular proliferation, increased apoptosis, altered autophagy and 112 
changes in RANKL/OPG, wnts/sclerostin expression have all been proposed to be important 113 
mediators of these effects. These mechanisms have been examined in animal models of disease and 114 
to some extent in human samples. We will conclude this section by discussing evidence that some of 115 
the adverse effects of glucocorticoids on systemic fuel metabolism are mediated through the 116 
skeleton. 117 
An important consideration when interpreting the literature relating to glucocorticoid effects on 118 
bone is to appreciate the significance and relationships of the various forms of glucocorticoids that 119 
have been studied or implicated in disease. The main glucocorticoid secreted from the adrenal 120 
cortex in humans is cortisol. When administered therapeutically, cortisol is referred to as 121 
hydrocortisone. A smaller amount of corticosterone (about 5-10% that of cortisol) is also secreted 122 
from the human adrenal cortex.11 Although traditionally considered to have a minor role in human 123 
physiology recent work examining the selective export of cortisol and corticosteroids from the cell 124 
suggests that corticosterone secretion could be important over and above the secretion of cortisol.9 125 
In the mouse and rat corticosterone is the main glucocorticoid secreted from the adrenal due to the 126 
absence of the 17alpha-hydroxylase enzyme in the adult adrenal gland in rodents.12 Cortisol and 127 
corticosterone have direct and similar actions at the glucocorticoid and mineralocorticoid receptors 128 
but in classical mineralocorticoid target tissues (kidney, colon, salivary and sweat glands) these 129 
glucocorticoids are inactivated by the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) 130 
to cortisone and dehydrocorticosterone respectively. These steroids lack activity at the level of the 131 
GR or MR but can be reactivated to cortisol and corticosterone by 11β-hydroxysteroid 132 
Comment [RSH3]: Again a figure here 
could be useful. Could we tie it into HPA 
axis, with relative circulating levels and the 
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dehydrogenase type 1 (11β-HSD1) enzyme which is expressed in a range of tissues, in particular in 133 
the liver but also in bone. Prednisolone and prednisone are the most widely used oral 134 
glucocorticoids. As with cortisol and cortisone these compounds differ by just a hydroxylation at 135 
position 11 of the steroid ring with prednisolone being the active form and prednisone the inactive 136 
form. In practice orally administered prednisone and prednisolone have similar properties in vivo 137 
since prednisone is efficiently converted to prednisolone by hepatic 11β-HSD1 activity on first pass 138 
metabolism in the liver.  139 
Endogenous glucocorticoids have the potential to bind to either the classical glucocorticoid receptor 140 
(GR) or the mineralocorticoid receptor (MR). The MR is also referred to as the type 1 or high affinity 141 
GR since the affinity of the MR for cortisol and corticosterone is 10 times higher than that of the 142 
GR.13 As discussed above, the main factor influencing endogenous glucocorticoid binding to the MR 143 
is the presence of 11β-HSD2. As a further complication, the synthetic glucocorticoid dexamethasone 144 
only binds to the GR and not the MR. These differences have important implications when 145 
interpreting differences between studies examining the mechanisms underlying GIOP. 146 
The downstream cellular consequences of glucocorticoid receptor binding have been reviewed in 147 
detail elsewhere.14,15 These mechanisms will be discussed in each section where specifically relevant 148 
to glucocorticoid actions on bone. 149 
 150 
II.I Effects on osteoblasts, osteocytes and osteoclasts 151 
Glucocorticoids have direct effects on specific tissues but also exert their effects through indirect 152 
mechanisms, e.g. through the regulation of endocrine signalling pathways. The extent to which 153 
glucocorticoid induced bone loss is mediated through direct effects on the cells which coordinate 154 
bone metabolism (osteoblasts, osteocytes, osteoclasts and their respective precursors) has been 155 
debated. Bone cells are clearly very sensitive to glucocorticoids in vitro and in vivo. In vivo mouse 156 
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models that have attempted to examine this question show that the effects of glucocorticoids on 157 
bone are primarily through direct actions on bone cells and bone remodelling. The situation 158 
regarding the important clinical manifestations of GIOP in humans, fractures, might be different 159 
since glucocorticoids can influence falls related factors such as muscle strength that are difficult to 160 
replicate in mice.  161 
Whether or not there is a single primary or dominant target of glucocorticoids accounting for the 162 
effects on bone remains unclear. This is not helped by the wide variety of mouse models which vary 163 
according to strain; age; sex; skeletal site examined; and type, dose, duration and route of 164 
glucocorticoid administration.16,17 Furthermore, the effects of glucocorticoids are not consistent 165 
across skeletal sites and surfaces. Although glucocorticoid treatment of mouse models mimics some 166 
of the findings seen with clinical use, the extent to which non-human models mirror the 167 
pathophysiology in humans remains unclear.  168 
In the following section the individual effects of glucocorticoids on 1, osteoblasts, 2, osteocytes, and 169 
3, osteoclasts will be discussed in terms of in vitro and in vivo actions. These sections reflect the 170 
majority of recent studies investigating how glucocorticoids affect bone. There is, however, a small 171 
number of studies that report consequences possibly mediated by other cells. For example, a 172 
preliminary report indicated that mice that lack lymphocytes are protected against glucocorticoid 173 
induced changes in bone density, suggesting a possible role for these cells in GIOP.18 174 
 175 
II.I.I Effects on osteoblasts 176 
In vitro effects: 177 
In contrast to the clearly detrimental impact that therapeutic glucocorticoids have on bone in the 178 
clinical setting in many in vitro situations, glucocorticoids have an important and positive role in the 179 
commitment and differentiation of cells of the osteoblast lineage. Glucocorticoids have a stimulatory 180 
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role in the differentiation of uncommitted mesenchymal precursor cells to the osteoblastic lineage 181 
and high doses of glucocorticoids are generally part of the differentiation medium in protocols for 182 
the differentiation of these cells.19,20 Glucocorticoids demonstrate clear stimulatory activity on the 183 
expression of a range of cellular markers related to osteoblast function, including osteocalcin and 184 
alkaline phosphatase.21-24  Glucocorticoids show inconsistent effects on cellular proliferation but in 185 
general high doses of glucocorticoids slows the proliferation rate of mature osteoblast like cells in 186 
culture.25 The observation that glucocorticoids in vivo usually result in a dramatic decrease in bone 187 
formation but in vitro actions are largely stimulatory has been difficult to explain. It is possible that 188 
there is dose dependency with low levels of glucocorticoids being stimulatory and high doses being 189 
inhibitory for osteoblasts.26 Other lines of evidence suggest that in vitro effects of glucocorticoids in 190 
culture are more complex than previously considered. For example, within a single primary culture 191 
of osteoblastic cells there are various different populations present. It has been suggested that more 192 
mature osteoblasts have stimulatory paracrine functions on less mature osteoblast precursors and 193 
that these are glucocorticoid dependent. For example, disruption of glucocorticoid signalling by the 194 
artificial introduction of 11β-HSD2 into mature osteoblasts results in reduced differentiation of less 195 
mature osteoblasts within the same culture, an effect likely due to alterations of expression of wnt 196 
or wnt-related genes.27 These results indicate that the communication between various types of 197 
bone cells at different stages of differentiation is likely to be complex and glucocorticoids appear 198 
important in these communication pathways. A recent review focussing on the various mechanisms 199 
by which glucocorticoids affect osteoblast function has been published by Frenkel et al.28 200 
Glucocorticoids influence the proliferation, differentiation or function of osteoblasts but most 201 
dramatically they influence their survival and death. It is now clear that osteoblast apoptosis has an 202 
important role in bone physiology.29 Glucocorticoids stimulate osteoblast apoptosis in vitro, 203 
triggering the rapid activation of the kinases Pyk2 and JNK and increasing reactive oxygen species 204 
(ROS) in primary cultures.30,31 Glucocorticoids can increase apoptosis via increased endoplasmic 205 
reticulum stress and glucocorticoid actions through this pathway synergise with TNFa.32 206 
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Glucocorticoids also regulate the expression and activity of pro-apoptotic factors of the Bcl2 family 207 
such as Bim.33 Knockdown of Bim in osteoblasts protects against glucocorticoid induced apoptosis 208 
and silencing of E4BP4 attenuates Bim expression and also blocks glucocorticoid induced apoptosis 209 
in osteoblasts.34 Glucocorticoids also increase expression of Bak (another Bcl2 family member) and 210 
decrease expression of Bcl-XL, a pro-survival Bcl2 protein.35 Dexamethasone can induce Bcl2 211 
mediated cell death via induction of p53. 36 As such there appears to be multiple pathways by which 212 
glucocorticoids induce apoptosis of osteoblasts. 213 
A vast range of studies have attempted to identify specific pathways by which glucocorticoids act on 214 
osteoblasts in culture. The most prominent targets proposed include: effectors of apoptosis, 215 
RANKL/OPG signalling, wnts and their inhibitors, microRNAs, IL-11 and BMP/notch signalling.  216 
Glucocorticoids stimulate expression of RANKL and suppress expression of OPG in primary cultures 217 
of osteoblasts and osteoblast like cell lines.37-39 These changes would be expected to generate a pro-218 
osteoclastogenic signal. The significance of osteoblast expressed RANKL has recently been 219 
questioned with the osteocyte now considered to be the most important source of RANKL in normal 220 
physiology.40,41 221 
Wingless (wnt) signalling is firmly established as a critical mediator of many of the anabolic and 222 
catabolic signalling pathways in bone.42 Glucocorticoids have dramatic impacts on a range of wnt 223 
related genes. At low doses glucocorticoids promote the secretion of wnt9a and wnt10b. At higher 224 
doses glucocorticoids suppress intracellular wnt signalling in osteoblasts resulting in a suppression of 225 
osteoblast differentiation.43,44 Significant interest has focussed on the synthesis of wnt inhibitors 226 
such as DKK-1 and sclerostin. Whereas sclerostin will be discussed in the next section since it is 227 
expressed exclusively in osteocytes, DKK1 is an important wnt inhibitor which is expressed in 228 
osteoblasts and reported to be positively regulated by glucocorticoids.45 DKK1 appears to have a 229 
negative impact on bone formation but also causes a reduction in the expression of OPG by 230 
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osteoblasts,46 which would favour an increase in osteoclastogenesis and bone resorption, in addition 231 
to the reported suppression of anabolic osteoblast behaviour. 232 
Other osteoblastic signalling pathways targeted by glucocorticoids include insulin-like growth 233 
factors, transforming growth factors, basic fibroblast growth factor, and platelet-derived growth 234 
factors. In vitro, glucocorticoids supress the expression of IGF I and PDGF, which possess anabolic 235 
mitogenic actions in osteoblasts, whilst reducing the anabolic actions of TGFb.47-49 Novel cellular 236 
targets in osteoblasts which appear to be influenced by glucocorticoids in vitro include IL-1150, E3 237 
ubiquitin ligases51 and microRNA-199a.25 238 
 239 
In vivo effects: 240 
Much of what we know about the impact of glucocorticoid on osteoblast function comes from 241 
animal models of GIOP. Although these models appear to recapitulate some of the features seen in 242 
human GIOP there is considerable diversity and variability in the phenotypes seen with the models 243 
used. This raises questions as to the applicability of these models to the human situation. Mouse 244 
models vary in terms of the strain used; the animal age and gender; the glucocorticoid type, route 245 
and dose employed; and the skeletal site examined. The C57/B6 mouse strain is increasingly 246 
employed as this background is generally most efficient when using tissue targeted transgenic 247 
models via the Cre/lox approach. Recent evidence suggests that this mouse strain is relatively 248 
resistant to the effects of glucocorticoids on bone compared to other mouse strains.52 It is not clear 249 
whether this reflects a bone specific difference in glucocorticoid sensitivity or a more generalised 250 
disparity. Although this variability between animal strains in terms of glucocorticoid sensitivity and 251 
mechanisms of glucocorticoid adverse consequences makes conclusions more difficult to draw, it is 252 
possible that what is seen in mice is some of the clinical variability seen in humans. The findings from 253 
mice models might need to be considered in their aggregate form rather than depending too much 254 
12 
 
on individual models. A comprehensive review of the various non-human models used to study GIOP 255 
has recently been published.16 In addition to being useful for the study of GIOP these models have 256 
also indicated that glucocorticoid signalling is important for normal mineralisation of vertebral bones 257 
and bone growth at some surfaces. 258 
The acceptance of mice as models for human GIOP started with a highly influential study which 259 
examined the Swiss Webster mouse strain treated with subcutaneous pellets of prednisolone.53 260 
These studies demonstrated that glucocorticoids could induce osteoblast and osteocyte apoptosis in 261 
vivo. The effects of glucocorticoids on osteoblasts appeared to dominate those on osteoclasts and 262 
bone resorption. The direct cellular targets of glucocorticoids within bone have been examined in 263 
subsequent studies utilising C57/B6 mice. These studies include tissue selective blockade of 264 
glucocorticoid signalling in specific cell lineages using the 11β-HSD2 enzyme or selective deletion of 265 
glucocorticoid receptors. A potentially important distinction between these approaches is that 266 
models using 11β-HSD2 will have reduced glucocorticoid signalling through both GR and MR if these 267 
receptors are present within target cells whereas selective GR or MR deletion will only target these 268 
aspects of glucocorticoid signalling. Another important caveat using these approaches is that it is 269 
now clear that the promoters used to drive selective expression within bone have some limitations 270 
in that expression in tissues of interest is not normally complete and expression of transgenes can 271 
occur to a limited extent in off target tissues, for instance in selective regions of the brain during 272 
development.54-56 This off target expression may differ between strains.  273 
11β-HSD2 is a glucocorticoid inactivating enzyme which has expression primarily in MR expressing 274 
tissues such as kidney, colon and salivary gland. There is additionally some expression within the 275 
brain and in fetal tissues.57,58 Osteoblastic cells (osteoblasts and osteocytes) in the adult mouse do 276 
not express 11β-HSD2 although the enzyme has been detected in fetal bone.59 11β-HSD2 is highly 277 
effective at reducing glucocorticoid signalling and when expressed in osteoblasts appears to entirely 278 
block the effect of physiological concentrations of endogenous glucocorticoids.60 The enzyme is also 279 
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effective at blocking the action of prednisolone.61 As such, transgenic expression of 11β-HSD2 within 280 
osteoblasts has been utilised to examine the impact of glucocorticoids on these cells. Expression of 281 
11β-HSD2 within osteoblasts has been reported in two different strains of mice with different 282 
promoters. In the C57/B6 strain, expression of 11β-HSD2 gene was under the control of the 283 
osteocalcin promoter and as such would be expected to be expressed in mature osteoblasts and 284 
osteocytes.61 These mice did not have an obvious basal phenotype but were protected against the 285 
actions of glucocorticoids on osteoblast apoptosis and loss of bone density. In the CD1 strain, 11β-286 
HSD2 has been driven under the control of the 2.3Kb ColIAI promoter.62,63 This truncated form of the 287 
full type I collagen promoter is expressed in mature osteoblasts and osteocytes but not in other cell 288 
types that normally produce type I collagen.64 These mice had a subtle basal phenotype with 289 
reduced bone density of the vertebrae implying an impairment of bone mineralisation.63 These mice 290 
also had delayed ossification of the cranial bones and reduced periosteal circumference of long 291 
bones indicating reduced periosteal apposition of bone.65,66 These mice were also protected against 292 
the adverse effects of glucocorticoids on bone, specifically the reduction in bone formation rate an 293 
increase in endosteal bone resorption seen in controls.67 294 
Mice with targeted deletion of the GR in osteoblastic cells have also been generated. These mice had 295 
Cre driven by the Runx2 promoter which is expressed in cells throughout the osteoblast lineage.50 296 
These mice had a basal phenotype characterised by mildly reduced bone size and reduced bone 297 
density. As with the mice above this strongly indicated that endogenous glucocorticoids are not 298 
essential for bone formation but do have a mild anabolic effect on bone. When treated with 299 
prednisolone these mice did not demonstrate the bone loss seen in their wild type equivalents. 300 
These negative effects of glucocorticoids still occurred in mice where the GR was modified such that 301 
it was not able to form dimeric complexes (the dim-dim mice). This implies that the actions of 302 
glucocorticoids on osteoblasts are mediated primarily by the monomeric form of the receptor (a 303 
mechanism associated with transrepression and typically associated with anti-inflammatory actions) 304 
rather than the dimeric form traditionally thought of as mediating the beneficial metabolic actions of 305 
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glucocorticoids. This study identified suppression of IL-11 as an important mediator of the adverse 306 
effects of glucocorticoids on bone. 307 
Although it has been generally assumed that the GR is the most important target of glucocorticoids 308 
in the osteoblast it has been reported that the MR is also expressed in these cells.68 In mouse models 309 
blockade of MR signalling either through the use of the MR antagonist spironolactone or through 310 
transgenic deletion of the MR results in some protection against the effects of therapeutic 311 
glucocorticoids.69 The relative importance of GR and MR signalling in bone and whether there are 312 
interactions between the GR and MR signalling pathways has not been determined. 313 
 314 
II.I.II Effects on osteocytes: 315 
Our understanding of the role that osteocytes play in the coordination of bone remodelling has 316 
developed rapidly over the last two decades. A role for osteocytes in the development of GIOP was 317 
suggested at an early stage and in particular a role for osteocyte apoptosis was demonstrated in 318 
animal models.53 Thus, osteocyte appears to be extremely sensitive to glucocorticoids.  319 
 320 
Evidence for osteocyte apoptosis. 321 
Evidence for a role of glucocorticoids in osteocyte function initially came from animal models of 322 
glucocorticoid treatment in which apoptosis of osteocytes could be demonstrated.53,70 These 323 
observations were supported by studies examining human bone from individuals that had been 324 
exposed to high levels of glucocorticoids where signs of osteocyte apoptosis were also seen.53,71 325 
Osteocytes are thought to be long-lived cells and it is uncertain whether osteocytes that have 326 
apoptosed can be replaced by new osteocytes. As such death of osteocytes would be likely to have 327 
prolonged consequences for the organism. Apoptosis of osteocytes was also demonstrated in mice 328 
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treated with a high dose of prednisolone (2.4mg/kg/d over 28 days) while osteocytes remained 329 
unaffected at a lower dose of 1.4mg/kg/d, suggesting that there may be a threshold for the 330 
development of osteocyte apoptosis.72 331 
Various factors have been found to protect against glucocorticoid induced apoptosis of osteocytes in 332 
animal models. These include PTH, bisphosphonates, calcitonin and OPG.73-76 Whether this 333 
mechanism contributes to the therapeutic efficacy of some of these agents in human GIOP is unclear 334 
and difficult to test clinically. 335 
It should be noted that osteocyte apoptosis in GIOP has not been a universal finding. Indeed, there 336 
was no evidence of osteoblast or osteocyte apoptosis in control mice treated with glucocorticoids in 337 
the study examining the effects of osteoblast/osteocyte specific deletion of GR on the sensitivity of 338 
bone to glucocorticoids.50 This lack of osteocyte apoptosis was manifest despite glucocorticoids 339 
having a clearly detrimental effect on bone formation and bone strength. It is possible that this 340 
observation reflects differences between strains and glucocorticoid dosing but it also implies that 341 
glucocorticoid induced apoptosis of osteocytes is not an essential step for glucocorticoids to have 342 
their negative effect on bone. In this context there may be a parallel with the clinical situations of 343 
osteoporosis and osteonecrosis. Therapeutic glucocorticoid administration can cause both but the 344 
development of clinically significant osteonecrosis is generally much rarer than that of osteoporosis.  345 
 346 
Glucocorticoid treatment has been demonstrated to induce significant structural changes in the 347 
environment of the osteocyte. Glucocorticoids adversely affect fluid flow in the canalicular network. 348 
77 This effect would be expected to have detrimental effects on osteocyte health but could also 349 
directly influence bone mechanical strength through effects on bone tissue hydration. Glucocorticoid 350 
treatment is also associated with an increase in mean osteocyte lacunar size.78 There is, in addition, 351 
a reduction in mineralisation in the bone adjacent to the osteocytes, a phenomenon referred to as 352 
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‘osteocytic osteolysis’.78 This suggests that part of the anatomical pathology involved GIOP could be 353 
microscopic changes to bone mineral properties through perilacunar osteolysis or 354 
hypomineralisation. The mechanism by which glucocorticoids cause these changes is not 355 
established. These changes could explain the relatively rapid change in fracture risk during 356 
glucocorticoid treatment and its reversibility. In addition, this type of microarchitectural change 357 
would reduce bone strength disproportionately to the change in BMD measured by DXA, thus 358 
accounting for the increased fracture risk observed for the same level of BMD in GIOP.  359 
The group that described the microscopic changes in osteocyte lacunae discussed above have 360 
attempted to define the cellular processes that are responsible for these changes. They found that 361 
glucocorticoid treatment was associated with expression of a range of genes in osteocytes 362 
associated with autophagy.72,79 Autophagy is a cellular pathway designed to maintain cellular 363 
homeostasis by degrading damaged organelles through formation of autophagasomes. Osteocytes 364 
are reported to respond to glucocorticoid treatment with an increase in autophagy markers and the 365 
accumulation of autophagosome vacuoles. It was hypothesised that autophagy maintained cell 366 
viability in the presence of glucocorticoids 79 The balance between protective autophagy clearance of 367 
damaged organelles and destruction of key cellular components may shift across tissue sites and 368 
with different glucocorticoid doses making its contribution to glucocorticoid mediated suppression 369 
of osteoblasts in vivo difficult to truly appreciate. Piemontese et al. tested whether genetic 370 
suppression of autophagy was associated with increased sensitivity of osteocytes to 371 
glucocorticoids.80 They deleted autophagy related gene 7 (Atg7), a gene central to the autophagy 372 
process, from osteocytes using the Dmp1Cre promoter. In control mice glucocorticoids stimulated 373 
autophagy in osteocytes and this was blocked in transgenic mice. However, there was no impact of 374 
autophagy suppression on the effects of glucocorticoids on bone. Interestingly, chemical inhibitors 375 
of autophagy have demonstrated protection against glucocorticoid induced bone loss and 376 
maintained bone formation.81 However, autophagy had now been reported to occur in osteoclasts 377 
exposed to glucocorticoids.82,83 Selective deletion of Atg7 in osteoclast precursors suppressed 378 
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glucocorticoid induced increases in bone resorption and bone loss in mice without any impact on 379 
osteoblast differentiation.82 Currently it appears that glucocorticoids induce autophagy in both 380 
osteocytes and osteoclasts but that the process in osteoclasts but not osteocytes impacts on bone 381 
strength. 382 
The osteocyte is now clearly established as being central to the process of bone remodelling through 383 
secretion of several key regulators of bone physiology.84 Osteocytes can generate OPG and RANKL. 384 
Glucocorticoids down regulate the production of OPG in osteocytes whereas the expression of 385 
RANKL appears unchanged. 85,86 Osteocyte secretion of RANKL appears to be a requirement for loss 386 
of cortical bone in mice treated with glucocorticoids.86 In this study glucocorticoids did not directly 387 
regulate RANKL in osteocytes but rather reduced the expression of OPG which allowed greater 388 
activity of the RANKL present. The osteocyte is also an important producer of wnt signalling 389 
antagonists such as sclerostin and DKK1. Glucocorticoids appear to increase the production of both 390 
sclerostin and DKK1 by osteocytes.51 The role of sclerostin in glucocorticoid induced bone loss has 391 
been examined in studies using anti-sclerostin antibodies and animals with genetic knockout of 392 
sclerostin. Treatment of mice with anti-sclerostin antibodies prevented the glucocorticoid induced 393 
reduction in bone formation seen with placebo treated mice.87 One study reported that these 394 
antibodies protected mice from glucocorticoid induced osteocyte apoptosis.88 A study using 395 
sclerostin/Sost knockout mice found that sclerostin deficiency protected against glucocorticoid 396 
induced bone loss but did not protect against a decrease in bone formation or an increase in 397 
osteoblast/osteocyte apoptosis.85 The protection appeared due to preservation of OPG levels and a 398 
protection against increased bone resorption that was seen in wild type mice.85 399 
These studies suggest that all of these molecules may have a role in different aspects of the effects 400 
of glucocorticoids depending on the model used. With regards to sclerostin and DKK1, it is currently 401 
unclear which particular pathway is most relevant in animals and humans. In particular it is not clear 402 
whether they both have essential roles or if there is compensation or redundancy between them. 403 
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 404 
Controversies in the field.  405 
A major issue is that osteocyte apoptosis should leave long standing consequences on bone since 406 
these cells are thought to be long lived. However, epidemiological studies indicate that the increased 407 
risk of fracture during treatment with glucocorticoids declines rapidly when the treatment is 408 
discontinued. It is possible that in humans there is a spectrum of osteocytic damage that can 409 
manifest as osteoporosis if the degree of osteocyte damage is modest, but as frank osteonecrosis if 410 
the degree of osteocyte damage is more extensive. It is also not clear why some studies in mice do 411 
not show any evidence of osteocyte apoptosis even when there are clearly negative effects of 412 
glucocorticoid treatment on other aspects of bone health. 413 
A further limitation is that the transgenic models discussed above which target glucocorticoid 414 
receptor signalling in osteoblasts also disrupt glucocorticoid signalling in osteocytes. To date, no 415 
osteocyte or osteoblast specific GR deletion model has been produced and evaluated in the context 416 
of GIOP. As such the relative contributions of osteoblasts and osteocytes to the observed 417 
phenotypes are not clear. It is possible that there may be independent contributions from both of 418 
these cell types which require a fuller exploration. 419 
 420 
II.I.III Effects on osteoclasts: 421 
The effects of glucocorticoids on osteoclasts have been examined in vitro and in vivo with indirect 422 
inferences being made through clinical studies. The examination of the role of osteoclasts in GIOP 423 
has been complicated since glucocorticoids appear to have direct effects on osteoclasts or their 424 
precursors but also have powerful indirect influences on osteoclastogenesis and osteoclast function 425 
via effects on osteoblasts and osteocytes.  426 
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In vitro studies have shed light on the direct actions of glucocorticoids in human osteoclasts where 427 
they increase resorption activity and pit formation.89,90 High doses of glucocorticoids are used in 428 
culture media to promote the growth and differentiation of osteoclasts.91 Greater mechanistic 429 
insights into these observations have come from murine osteoclast culture studies where addition of 430 
glucocorticoids prolongs longevity through their activation of the GR receptor.92,93 However, these 431 
same studies have identified that therapeutic glucocorticoids are also able to supress osteoclast 432 
differentiation and activation in vitro by increasing apoptosis and interfering with cytoskeletal 433 
reorganisation and rendering them less responsive to the pro-osteoclastogenic actions of M-CSF.92,93 434 
Similarly, osteoclast activity is suppressed within cultures of osteoclast in rats as a result of increased 435 
apoptosis in response to glucocorticoids.94 Overall, similar to what has been found in osteoblasts, 436 
the effects of glucocorticoids on osteoclast formation and bone resorbing capacity appear to be dose 437 
dependent with mostly stimulatory actions at low concentrations and inhibitory effects at very high 438 
concentrations. 439 
The effects of glucocorticoids on osteoclasts in vivo have been examined in murine models of 440 
glucocorticoid excess.93,95,96 Bone resorption/osteoclast activity is increased during early treatment 441 
with glucocorticoids supporting in vitro observations that glucocorticoids increase the survival of 442 
osteoclasts. Targeted abrogation of glucocorticoid signalling in osteoclasts using 11β-HSD2 443 
expression resulted in protection against this initial increase in osteoclast activity in mice treated 444 
with prednisolone.93 However, with prolonged exposure to high levels of glucocorticoids the number 445 
of osteoclasts is reduced due to a delay in the differentiation of new osteoclasts.92  446 
The most provocative studies in this area examined the deletion of the GR in osteoclasts using the 447 
LysMCRE transgene.92 LysMCRE is expressed in cells of the monocyte/macrophage lineage including 448 
osteoclasts. The mouse strain had a mixed 129/C57 genetic background. Rather than generating an 449 
osteoclastic phenotype the main consequence of osteoclast GR deletion was unexpectedly protected 450 
against the fall in bone formation during treatment with dexamethasone (10mg/kg daily injections) 451 
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as assessed by mineral apposition rate and serum osteocalcin levels. The osteoblasts did not appear 452 
to be protected against glucocorticoid-induced apoptosis. This study implies that at least some of 453 
the effects of glucocorticoids on the osteoblast might be mediated via the osteoclast. No mechanism 454 
for such communication was identified. Although not examined in this context several established 455 
signalling pathways by which osteoclasts can potently suppress bone formation have been 456 
reported97,98 giving these findings plausibility despite their sharp contrast with most of the existing 457 
literature.  458 
Similar studies using osteoclast GR deletion have failed to show the same effect. Prednisolone 459 
treatment of another mouse (Balb/c background) with GR knockout using the LysMCRE transgene did 460 
not demonstrate any protection against the reduction in bone formation as assessed by bone 461 
formation rate.50 Likewise, the expression of 11β-HSD2 within osteoclasts using the tartrate resistant 462 
acid phosphatase (TRAP) promoter in the FVB/N mouse strain failed to protect mice against a 463 
decrease in bone formation as assessed by serum osteocalcin levels in response to treatment with 464 
slow release prednisolone pellets.93 It is possible that these differences relate to subtle differences in 465 
strain, glucocorticoid dose or experimental set up. For instance the data regarding the effect of 466 
osteoclasts on bone formation examined the growth of the calvarial bone surface.92 As discussed 467 
earlier the outer cortex of bone seems to respond differently to glucocorticoids67 and thus the 468 
choice of surface may be an important factor in these results. Overall, given that there is only one 469 
study in support, on the current balance of evidence a significant role for osteoclasts in 470 
glucocorticoid induced suppression of bone formation throughout the skeleton appears unlikely. 471 
 472 
Summary: 473 
Glucocorticoids have multiple effects on osteoblasts, osteocytes and osteoclasts (summarised in 474 
figure…). Many of these effects appear to be individually very powerful in determining specific 475 Comment [M5]: Need to add figure. 
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phenotypes when examined in mouse models and this implies that no single mechanism is likely to 476 
mediate all of the effects seen in the clinical setting. Reduced bone formation at trabecular bone 477 
sites and increased endocortical resorption appear to be the most consistent pathological findings. 478 
The results appear to indicate that the osteocyte is the most important target of glucocorticoids but 479 
several major signalling pathways and cellular processes are all affected simultaneously. It should 480 
also be noted that none of the studies described above examined the effects of glucocorticoids in 481 
the context of inflammation. Clinical studies of patients treated with therapeutic glucocorticoids for 482 
various conditions consistently demonstrate that inflammation and the activity of the underlying 483 
disease being treated can have a substantial effect on bone independent of glucocorticoid use or 484 
more likely through complex interactions between glucocorticoids, the underlying illness and bone 485 
metabolism. 486 
 487 
II.II Other endocrine and non-endocrine effects on bone 488 
Glucocorticoids have effects on bone independent of their direct actions on bone cells. These effects 489 
are however difficult to study in animal models, particularly those that do not simulate an underlying 490 
disease being treated. Therapeutic glucocorticoids are well known to reduce sex steroid levels and 491 
this could have an adverse impact on bone.99 The reduction in sex steroid levels is likely to be greater 492 
in people with serious inflammatory illness which in itself is likely to impact on the hypothalamo-493 
pituitary-gonadal axis.100 Evidence in support of this notion comes from clinical trial data which 494 
indicate that premenopausal women are relatively protected against the effects of glucocorticoids 495 
on fracture risk.101 Clinical studies have indicated that estrogen treatment of post-menopausal 496 
women102,103 or testosterone (but not nandrolone) treatment of men104 taking glucocorticoids results 497 
in an increase in spine but not hip bone density (as measured by DXA). No fracture data are 498 
available. In women taking glucocorticoids who are already taking HRT there does not appear to be 499 
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any increase in bone density with continued use whereas the addition of intermittent PTH injection 500 
substantially improves BMD at the spine.105  501 
Glucocorticoids also have complex effects on calcium, vitamin D metabolism and parathyroid 502 
hormone. The literature relating to these actions is relatively old but indicates that glucocorticoids 503 
interfere with intestinal calcium absorption and increases renal calcium excretion.106 Early research 504 
also suggested a role for altered parathyroid hormone levels in the pathogenesis of GIOP.107 505 
However, a comprehensive review failed to find strong evidence for a role of parathyroid hormone 506 
in the detrimental effects of glucocorticoids on bone.108  507 
The effects of glucocorticoids are also attributable to changes in other circulating or locally produced 508 
hormones. The GH/IGF1 axis is known to have anabolic effects on bone growth and bone density.109 509 
These hormones are suppressed by high levels of glucocorticoids. Many in vitro studies have 510 
indicated that the suppressive effects of glucocorticoids on osteoblast function can be partially 511 
reversed by GH and/or IGF1 treatment.109 However, there are very few clinical studies examining this 512 
issue. Small studies in which children taking glucocorticoids for inflammatory bowel disease or 513 
arthritis were treated with GH indicated that GH therapy could improve some measures of bone 514 
formation and reverse effects of glucocorticoids on growth but these studies lacked control 515 
groups.110,111 516 
Glucocorticoids also have adverse effects on muscle strength, which known to influence bone 517 
strength through mechanical loading 112. This association of glucocorticoids with muscle strength is 518 
well characterised in Cushing’s disease where proximal myopathy is a characteristic and relatively 519 
specific feature of glucocorticoid excess. These actions are mediated through inhibition of 520 
myogenesis and increased proteolysis and atrophy of muscle fibres.113-115 As a consequence, 521 
glucocorticoid treatment appears to be a risk factor for falls. However, as discussed elsewhere, in a 522 
disease situation it is very difficult to disentangle the effect of glucocorticoid treatment from that of 523 
the underlying disease. Indeed, in certain inflammatory myopathies including polymyositis and 524 
23 
 
dermatomyositis the application of therapeutic glucocorticoids protects against muscle wasting 525 
through the suppression of disease activity.116 Some evidence supporting a positive role of 526 
endogenous glucocorticoids in maintaining muscle mass during inflammatory disease comes from 527 
mice in which 11β-HSD1 expression in muscle has been deleted.117 These mice have normal muscle 528 
size and characteristics in the basal state but in response to inflammation, muscle loss is much 529 
greater in 11β-HSD1 deficient mice. These data highlight the clinical dilemmas in treating 530 
inflammatory muscle and joint diseases with glucocorticoids, where such treatment may result in 531 
detrimental, neutral or strongly positive effects on muscle strength and falls risk, depending on the 532 
impact of glucocorticoids on the underlying illness. 533 
 534 
II.III Metabolic consequences mediated through bone cells 535 
In addition to the deleterious effects of therapeutic glucocorticoids on bone, these medications are 536 
also associated with an increased risk of impaired glucose tolerance, diabetes or, in people with pre-537 
existing diabetes, worsening of diabetic control.118,119 These effects have previously been assumed to 538 
be due to actions of glucocorticoids on tissues classically associated with insulin secretion or 539 
sensitivity such as the liver, muscle and pancreas.118 However, recent studies suggest that there may 540 
in addition by a role for bone in the development of dysmetabolism associated with glucocorticoid 541 
treatment120. 542 
Multiple studies in mice indicate that osteocalcin has metabolic effects. In particular osteocalcin, and 543 
in particular the uncarboxylated form of osteocalcin, appear to improve glycemic control and insulin 544 
sensitivity through effects on insulin secretion and insulin sensitivity.121 Cross-sectional studies in 545 
humans also demonstrate correlations between serum undercarboxylated osteocalcin and diabetes 546 
risk.122 The exact molecular pathways affected are unclear particularly since the identity of the 547 
24 
 
osteocalcin receptor(s) is still uncertain, although some candidates have been proposed such as the 548 
GPRC6A receptor.123  549 
Given that the level of osteocalcin in the circulation is dramatically reduced by therapeutic 550 
glucocorticoids it was hypothesised that some of the effects of glucocorticoids on systemic 551 
metabolism might be mediated by the glucocorticoid induced reduction of circulating osteocalcin 552 
concentrations. Studies using 11β-HSD2 transgenic mice which, as discussed above, selectively 553 
express 11β-HSD2 in osteoblasts and osteocytes, demonstrated that the glucocorticoid induced 554 
reduction in serum osteocalcin levels was substantially reduced when glucocorticoid-signalling in 555 
osteoblasts was disrupted. Furthermore, these mice had preserved glucose tolerance compared to 556 
littermate control mice that did not have 11β-HSD2 expression in bone.121 This protection against 557 
the effects of glucocorticoids on glucose tolerance was also seen in wild type mice in which 558 
osteocalcin was heterotopically and constitutively expressed in the liver. This rescuing of the 559 
dysglycemic phenotype was seen with heterotopic expression of either wild type osteocalcin (which 560 
would be expected to be carboxylated in vivo) or a mutant form of osteocalcin which lacked the 561 
ability to be carboxylated. It is unclear whether similar protection might exist in humans.  562 
An alternative approach has been to examine any possible impact of bone active treatments in 563 
patients treated with glucocorticoids. It is known that bisphosphonates reduce, and teriparatide 564 
stimulates osteocalcin synthesis and as such these treatments might result in differences in glycemic 565 
control when used in the treatment of GIOP. One small prospective study involving 111 people 566 
taking glucocorticoids that were treated with either bisphosphonates or teriparatide reported a 567 
small but significant decrease in HbA1c in people who took teriparatide whereas there was no 568 
change in HbA1c in those that took bisphosphonates or just calcium and vitamin D.124  569 
Although osteocalcin has been the most studied mediator of effects of bone on systemic metabolism 570 
it is likely that other pathways exist. These pathways have been reviewed elsewhere but have not 571 
yet been examined in the context of glucocorticoids and bone.125,126 572 
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Given that there is a role for excess glucocorticoids in the development of systemic dysmetabolism 573 
there is a possibility that endogenous glucocorticoids have a similar influence on systemic 574 
metabolism via an action on bone. Circumstantial evidence for this exists in that transgenic deletion 575 
of 11β-HSD1 globally protects mice against the adverse effects of glucocorticoids on energy 576 
metabolism.127 However, deletion of 11β-HSD1 in classical target tissues of glucocorticoids such as 577 
liver, fat or muscle failed to prevent these effects suggesting that other tissues also contribute to the 578 
adverse metabolic phenotype seen with glucocorticoid exposure. 579 
  580 
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III Endogenous glucocorticoids and bone 581 
In this section we will review data relating to the effects of endogenous glucocorticoid excess on 582 
bone. We will review the bone phenotype in Cushing’s disease but also more subtle states of 583 
autonomous states of circulating glucocorticoid excess. We will then examine the role of tissue 584 
specific changes in glucocorticoid action focussing primarily on the role of 11β-hydroxysteroid 585 
dehydrogenase enzymes.  586 
 587 
III.I States of circulating glucocorticoid excess, Cushing’s disease and autonomous cortisol 588 
production 589 
III.I.I Bone disease in Cushing’s disease/syndrome. 590 
As discussed in section II.1, there is strong evidence that endogenous glucocorticoids are required 591 
for normal bone metabolism and osteoblastogenesis.63,128 In contrast, in Cushing’s disease and other 592 
clear cut forms of endogenous circulating glucocorticoid excess, there is normally a substantial 593 
negative impact on bone (reviewed in Toth and Grossman129). This was recognised early on by 594 
Cushing, and bone related complications of Cushing’s disease are clearly evident in clinical practice.1 595 
More recent studies that have attempted to quantify the bone effects of endogenous Cushing’s 596 
syndrome have generally been small (up to around 180 patients) and varied according to the 597 
number of patients with each underlying cause of Cushing’s (pituitary, adrenal, ectopic, 598 
adrenocortical cancer etc.), and length of time before diagnosis was made. Despite this diversity, the 599 
studies have been very consistent in indicating a substantially increased risk of fracture (typically a 600 
fracture prevalence of 50% is reported) and a greater chance of having very low bone density (below 601 
a T-score of -2.5) when assessed by DXA. The incidence and prevalence figures depend on the extent 602 
to which fractures are searched for. In a self-report survey of 125 patients with endogenous 603 
Cushing’s syndrome and age and sex matched controls, fracture risk appeared to be elevated 604 
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substantially in the 2 years prior to diagnosis with an incidence rate ratio of 6 in patients with 605 
Cushing’s syndrome.130 Interestingly there was no evidence of an increased risk of fracture prior to 2 606 
years before the diagnosis. Additionally, after successful treatment the reported fracture rate was 607 
also no different from that of controls. Although an important study with a high (83%) response rate, 608 
the data was limited by the study’s focus on clinical fractures.  609 
This type of analysis cannot accurately determine the risk of vertebral fractures. Vertebral fractures 610 
are frequently misdiagnosed or missed. As a consequence, the overall rate of vertebral fractures of 611 
any origin is usually grossly underestimated unless examined for specifically.131 Vertebral fractures, 612 
even if asymptomatic, are amongst the strongest risk factors for further fracture and premature 613 
mortality.131,132 The standard approach to the diagnosis of vertebral fractures is to examine for loss 614 
of vertebral height on spine radiographs using the Genant classification (with a fracture defined as a 615 
loss of anterior vertebral height of 20% or more)133. A study by Tauchmanova et al. focussed 616 
particularly on the risk of spine fractures in patients with endogenous Cushing’s syndrome of various 617 
etiologies and examined spine radiographs in cases and controls.134 In an analysis of 80 patients and 618 
80 controls, vertebral fractures were present in a remarkable 76% of patients with Cushing’s. In an 619 
equally remarkable 85% of patients with a vertebral fracture, multiple fractures were present. Only 620 
24% of spine fractures were known to the patient.  621 
A comprehensive and contemporary analysis of bone disease in a cohort of patients with 622 
endogenous Cushing’s syndrome was reported by Belaya et al.135 All patients had chest radiographs 623 
and AP and lateral spine radiographs. In 182 patients studied, 81 patients had fractures. 70 of these 624 
patients had fractures of the spine. 53 out of these 70 patients had multiple vertebral fractures. Out 625 
of over 150 fractures just 7 were non rib, non-vertebral fractures. These figures indicate that 626 
prevention of spine fractures should be the major skeletal priority in patients with endogenous 627 
Cushing’s syndrome. 628 
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Although Cushing’s syndrome is associated with bone loss (as assessed by DXA) and osteoporotic 629 
fractures, the utility of bone mineral density scans in predicting fracture is limited. In the studies 630 
described above, fractures (and in particular spine fractures) occurred in some patients with 631 
relatively well preserved BMD.134 In the largest study, bone density measured by DXA was not 632 
predictive of fracture in a multivariable model that took into account the severity of 633 
hypercortisolaemia.135 The only predictor of fracture in this study was the severity of Cushing’s. 634 
However in an earlier study spine BMD was a predictor of vertebral fracture in Cushing’s.134 Since the 635 
severity of Cushing’s is associated with reductions in bone mass it is likely that the severity of 636 
Cushing’s and the decrease in measured BMD both provide clinically useful information in the 637 
assessment of fracture risk in these patients. Trabecular bone score (TBS; a non-invasive measure of 638 
trabecular bone architecture derived from spine DXA scans) has also been evaluated in patients with 639 
Cushing’s.135 Values were found to be significantly reduced (indicating impaired trabecular bone 640 
structure) but the scores did not have predictive value in estimating the risk of vertebral bone 641 
fracture. Advanced imaging techniques such as high resolution peripheral quantitative CT (HR-pQCT) 642 
and hrQCT of vertebral bone, and techniques for in vivo examination of material properties such as 643 
microindentation, which have all been used in patients treated with  glucocorticoids, have not yet 644 
been reported in patients with Cushing’s. 645 
Other potential predictors of fracture have also been examined in Cushing’s. In one study fracture 646 
risk at the spine appeared to be independent of the presence of menstrual irregularities with 647 
amenorrheic women having a similar risk of fracture and BMD to those with eumenorrhea.134 648 
Another study however suggested that reduction in BMD was more likely in women with estrogen 649 
deficiency.136 Fracture risk was higher in patients with ectopic ACTH syndrome, presumably as a 650 
result of the higher cortisol levels usually found in this condition.134 Serum osteocalcin levels have 651 
also been associated with fracture risk but again this relationship appears to be mediated by the 652 
levels of cortisol present.135 In terms of prediction of changes in BMD, the correlation between the 653 
extent of reduction in BMD and degree of cortisol excess has been reported in eumenorrheic women 654 
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with Cushing’s.137 The extent of reduction of BMD in patients with Cushing’s has also been 655 
associated with the duration of disease.136 656 
Whereas fracture risk in Cushing’s has been quantified in only a small number of studies, changes in 657 
biochemical markers of bone turnover have been assessed in at least 16 reports (reviewed in129). A 658 
finding in all but one of these studies is that serum osteocalcin levels are considerably decreased in 659 
Cushing’s. The results for other formation markers (PINP, PICP, alkaline phosphatase) show less, if 660 
any, change. Bone resorption markers do not appear to change in a consistent fashion in Cushing’s. 661 
The sensitivity of osteocalcin expression to glucocorticoids is well known and in this situation serum 662 
osteocalcin levels might be viewed as a marker of bone tissue glucocorticoid exposure rather than a 663 
true bone formation marker. The relationship of low serum osteocalcin with excessive cortisol levels 664 
is so strong that serum osteocalcin has been proposed as a diagnostic marker of Cushing’s 665 
syndrome.138 In a group of patients with Cushing’s syndrome serum osteocalcin levels were found to 666 
be highly correlated with serum cortisol measured at 0800 hrs, 2400 hrs and after a low dose 667 
dexamethasone suppression test. In a follow up study, the diagnostic utility of serum osteocalcin in 668 
patients presenting with obesity and risk factors for Cushing’s syndrome was evaluated.139 It was 669 
found that osteocalcin had a sensitivity of 74% and a specificity of 97% for the identification of 670 
Cushing’s syndrome. Additional prospective studies will be required to fully evaluate the clinical 671 
utility of osteocalcin as a diagnostic tool in Cushing’s syndrome.   672 
The changes in bone status in response to successful therapy have also been evaluated. In the self-673 
report survey of patients with Cushing’s syndrome described above the risk of fracture did not 674 
appear to be elevated after treatment.130 This study was likely to have modest sensitivity in terms of 675 
fracture detection given the relatively small number of patients available and the lack of detailed 676 
analysis of spine fractures. Studies consistently report a rise in BMD after successful treatment.140-143 677 
Although pre-disease BMD is clearly not available in the majority of people it is reported that the 678 
deficit in bone mass is largely reversible, at least in younger patients.142 These changes appear 679 
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relatively complex and vary between skeletal sites. Successful treatment is associated with an 680 
improvement in spine areal BMD but also an increase in bone area.140 This suggests the possibility of 681 
new bone being laid down on the outside of the vertebral bones (periosteal apposition) when 682 
glucocorticoid levels are restored to normal. Intriguingly, after successful treatment bone density 683 
and bone area at the wrist were actually reported to decrease.140 Although the authors proposed 684 
that this reflects a redistribution of bone from the appendicular to the axial skeleton it is unclear 685 
how such redistribution might occur, particular in relation to bone area, as this would require 686 
removal of bone from the outer cortex of the bone. The results are in keeping with the findings in 687 
mice that formation of bone at the outer cortex of some bones of the peripheral skeleton is actually 688 
stimulated by glucocorticoids rather than being suppressed.66 Serum osteocalcin also increases 689 
rapidly after treatment.138 Whereas there is no correlation between serum osteocalcin and other 690 
bone markers prior to treatment, shortly after successful treatment a strong correlation between 691 
osteocalcin and bone resorption markers develops (as is normally seen in populations of healthy 692 
people).138 As such, serum osteocalcin levels appear to primarily reflect cortisol levels in patients 693 
with Cushing’s prior to treatment, in treated patients they behave more like a traditional marker of 694 
bone formation. Although the data in general suggest a reversal of bone disease in patients 695 
successfully cured caution should be taken if patients need long term glucocorticoid replacement 696 
after cure. In a group of patients successfully cured the continuing use of glucocorticoid replacement 697 
was associated with reductions in BMD, BMC and osteocalcin compared to matched controls.136 698 
These effects were most evident in women with coexisting estrogen deficiency. This exaggerated 699 
sensitivity of estrogen deficient women is in keeping with the greater risk of fracture of post-700 
menopausal women treated with therapeutic glucocorticoids (discussed in section IV.1). As such, 701 
glucocorticoid replacement must be particularly carefully monitored in this group. 702 
 703 
III.I.II Bone disease is autonomous cortisol secretion. 704 
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More subtle states of glucocorticoid excess also appear to detrimentally impact on bone. Most 705 
attention has focussed on the concept of subclinical endogenous hypercortisolism, also referred to 706 
as subclinical Cushing’s and more recently autonomous cortisol secretion.144,145 This condition is in 707 
principle defined by abnormal cortisol secretion in the absence of clinical features of glucocorticoid 708 
excess. It is usually associated with nodules of the adrenal cortex (adrenal incidentaloma, AI). The 709 
condition is controversial and the best diagnostic criteria have yet to be established. In various 710 
studies the criteria differ but the most common component of the diagnosis is failure to suppress 711 
serum cortisol after a 1mg dexamethasone suppression text (DST).144 Depending on the definition 712 
the condition appears to be relatively common and is driven by the background prevalence of AIs. 713 
The prevalence of AIs based on radiographic series depends heavily on age but in is estimated that 714 
3% of people aged 50 have an adrenal nodule whereas up to 10% of elderly individuals may have 715 
AIs.144 It has been estimated that up to 30% of patients with AIs have some degree of autonomous 716 
cortisol secretion7 and as such up to 1-3% of the population aged 50 and above might have 717 
autonomous cortisol secretion.  718 
The research examining the relationship between bone health and the presence of autonomous 719 
cortisol secretion (usually in the context of patients known to have AI) is dominated by the studies of 720 
Chiodini and colleagues. These include cross-sectional, longitudinal, retrospective and prospective 721 
studies examining bone density, bone markers and fracture prevalence and incidence in these 722 
individuals. Most studies reported a reduction in BMD at the spine as assessed by either DXA146,147 or 723 
qCT.148,149 Trabecular bone score has also been reported to be lower and to predict the development 724 
of fracture in this group of patients.147 As with bone changes in Cushing’s disease the data relating to 725 
the change in BMD at the hip is less clear with some studies indicating a reduction in BMD and some 726 
no change. Differences between studies are likely due to the relatively small number of patients 727 
examined in most studies and heterogeneity in the proportions of men, pre-menopausal and post-728 
menopausal women. Again, in a similar fashion to that seen with endogenous Cushing’s syndrome, 729 
autonomous cortisol secretion is reported to be associated with a decrease in blood osteocalcin 730 
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levels but no consistent changes in other markers or bone formation or markers of bone resorption. 731 
These studies were however relatively small with typically less than 50 patients. 732 
The most dramatic findings in these studies are the presence of vertebral fractures. A recent meta-733 
analysis of these studies found that the prevalence of radiographically identified vertebral fractures 734 
was 63.6% (CI 56-71%) in patients with autonomous cortisol secretion compared to a prevalence of 735 
16% (CI 5-28) in controls.7 Interestingly, patients known to have AI that do not meet the criteria for 736 
autonomous cortisol secretion were reported to have a higher prevalence of spine fractures (28%) 737 
than controls without AI (20-35). This suggested to the authors that some patients with AI with 738 
excessive production of cortisol might not be detected by current tests and by implication that all AIs 739 
are a risk factor for fracture. The authors of the meta-analysis could not identify any patient related 740 
factors that predicted the development of fractures beyond the presence of autonomous cortisol 741 
secretion. A study of 570 patients with AIs attempted to determine the threshold cortisol level post 742 
1mg DST (using an Abbott TDxFLs cortisol assay) which is best able to predict the presence and the 743 
future development of vertebral fractures.150 It was found that a post DST cortisol level of greater 744 
than 2.0 microgram per decilitre (55 nmol/L) was the best criteria in both situations with sensitivities 745 
and specificities between 68 and 80%. The presence of cortisol levels above this threshold was 746 
associated with an odds ratio of fracture of over 10.  747 
These prevalence and incidence rates of vertebral fracture in people with AI are extremely high and 748 
could represent a large burden of disease that is currently not being addressed. However, the 749 
proportion of these fractures that actually cause symptoms or otherwise impact on patient well-750 
being is unknown. Although difficult to perform, future trials would ideally aim to determine 751 
whether AIs (with or without autonomous cortisol secretion) are associated with a greater risk of 752 
clinical vertebral fractures, height loss, kyphosis development or reduced quality of life relating to 753 
musculoskeletal health. An alternative way of assessing whether autonomous cortisol secretion 754 
relating to AIs is associated with clinically significant vertebral fracture is to examine the prevalence 755 
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of these abnormalities in patients presenting with clinical vertebral fracture. In one study 7 out of 65 756 
patients presenting with osteoporosis and spine fracture were found to have subclinical 757 
hypercortisolism.151 In a subsequent study of over 600 patients with osteoporosis and no apparent 758 
cause the rate of subclinical hypercortisolemia was significantly lower at 1.3%.152 These patients 759 
however had a relatively low rate of reported fracture and in particular of clinical vertebral fracture. 760 
On the basis of what is known about endogenous Cushing’s and subclinical Cushing’s it is reasonable 761 
to assume that the development of a vertebral fracture rather than just a low BMD by DXA would be 762 
a more sensitive indicator of the presence of abnormal cortisol secretion. 763 
Remaining questions in this area include the most appropriate treatment approach to a patient with 764 
bone disease related to autonomous cortisol secretion by AI and when and how to investigate for 765 
the presence of autonomous cortisol secretion in patients presenting with bone disease. A recent 766 
study suggested that adrenalectomy was effective at reducing the risk of new vertebral fracture over 767 
a follow up period of 28-40 months.153 This study was limited by a lack of randomisation. In the 768 
absence of randomised clinical trials it would be reasonable to consider the option of adrenalectomy 769 
in patients with AI, autonomous cortisol secretion and bone disease, particularly in the presence of 770 
other conditions that might be exacerbated by cortisol excess such as hypertension and diabetes. An 771 
additional option is the use of medications that are proven to be effective in the treatment of 772 
idiopathic osteoporosis or GIOP associated with therapeutic glucocorticoid use. There is additionally 773 
data based on a small number of people that indicates that the bisphosphonate clodronate is 774 
effective in increasing BMD at the lumbar spine in subclinical Cushing’s.154 No guidelines are 775 
available for use of possible medical therapies in this particular situation. The use of treatment 776 
should also consider that the most common site of fracture in this condition is the spine, BMD can 777 
be selectively reduced at the spine and bone density may not fully predict fracture risk associated 778 
with glucocorticoid excess. Fracture risk calculators such as FRAX and the Garvan Fracture Risk 779 
calculator are based on hip density and might underestimate the risk of vertebral fractures in this 780 
condition. 781 
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It remains unclear whether patients with post-menopausal and age related osteoporosis and no 782 
symptoms of hypercortisolemia should be tested routinely for the condition. A pragmatic approach 783 
at the current time would be to test those individuals who have a higher likelihood of cortisol excess 784 
e.g. people presenting with vertebral fractures, people with BMD values that are highly discordant 785 
between spine and hip with spine being low, and people with non-traumatic fractures that occurred 786 
in the context of relatively normal bone density. The most appropriate test to identify people with 787 
excess cortisol secretion that is likely to impact on bone would appear to be the 1mg DST with a cut-788 
off of 2 micrograms per decilitre (55 nmol/L) (although these values should be adjusted based on the 789 
performance of the local cortisol assay).7,150,151 Clearly the distinction between autonomous cortisol 790 
secretion and overt Cushing’s syndrome might be difficult in these situations where there is clear cut 791 
bone disease in association with abnormal cortisol secretion. In these situations additional 792 
investigations are required to determine the basis for the abnormal cortisol levels. 793 
 794 
III.I.III Bone impact of physiological variation in the HPA axis. 795 
It is possible that individual variations in the circulating level of endogenous glucocorticoids might 796 
also have an impact on bone even in the absence of any disease or condition affecting the HPA axis. 797 
By examining healthy post-menopausal women before and after treatment with the adrenal 798 
corticosteroid synthesis inhibitor metyrapone it has been established that the circadian variation in 799 
serum osteocalcin is influenced by adrenal cortisol secretion.155 In the same study, other bone 800 
formation or resorption markers did not appear to be influenced by adrenal function suggesting a 801 
specific sensitivity of osteocalcin to glucocorticoids independent of its role as a marker of bone 802 
formation. Whether variations in adrenal cortisol secretion impacts on bone health has been 803 
primarily examined in studies looking at serum or salivary cortisol levels and differences in bone 804 
health (mostly assessed as BMD by DXA) during ageing. These studies have generally found weak 805 
associations between levels of circulating glucocorticoids at various time of day and either current 806 
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bone density or change in bone density over time. The results also appear to differ depending on 807 
whether women or men are studied. In the a study of 228 elderly community dwelling people 808 
salivary cortisol levels at 2300 were negatively associated with lumbar spine BMD in women 809 
whereas in men 0700 salivary cortisol levels negatively correlated with spine BMD.156 In 34 healthy 810 
elderly men that had frequent serum cortisol measurements over a 24 hour period the integrated 811 
serum cortisol level over the 24 hour period was negatively associated with lumbar spine BMD. 812 
Additionally, trough cortisol predicted the rate of bone loss at the spine and femoral neck over the 813 
subsequent 4 years.157 In a study of over 500 men and women from the Longitudinal Ageing Study 814 
Amsterdam serum fasting cortisol was associated with lower BMD at the femoral neck after 815 
adjustment for age and BMI.158 A study of 135 elderly women and 171 men examined the 816 
relationship between serum cortisol, serum cortisone, bone markers and BMD.159 It was found that 817 
serum cortisol had no relationship with any bone measurements but serum cortisone was negatively 818 
associated with serum osteocalcin levels and spine BMD. These relationships were independent of 819 
the levels of cortisol. This study suggests that the relationship between adrenal corticosteroid 820 
production and bone health may, at least in part, be mediated via cortisone. The only other study 821 
that explored the role of cortisone in bone health performed a comprehensive analysis of adrenal 822 
corticosteroid output and metabolism in young males in relation to bone development at the 823 
proximal radius. In this study the level of urinary cortisone metabolites was independently and 824 
negatively associated with reduced bone density.160  825 
A significant limitation of these studies is their lack of information relating to fractures. Two studies 826 
have however provided information in relation to fracture risk and adrenal corticosteroid 827 
production. A sub-study of the MacArthur Study of Successful Ageing measured overnight (between 828 
2000 to 0800 hrs) urinary free cortisol excretion in 684 men and women aged 70-79 at baseline.161 829 
Higher baseline UFC was significantly associated with the incidence of self-reported fractures over 830 
the next 4 years. These relationships appeared to be relatively strong e.g. in the highest quartile of 831 
UFC the adjusted odds of a fracture was over 5. A more recent cross-sectional study examined the 832 
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relationship between salivary cortisol measurements taken at various times of the day and the TBS 833 
and presence of vertebral fractures.162 The study involved over 600 women and vertebral fractures 834 
were defined on the basis of Genant grade 2 or greater fractures on spine radiographs. This criteria 835 
(a loss of height of greater than 25%) is more stringent than that typically used in the studies 836 
examining spine fractures in people with subclinical Cushing’s described above and would be 837 
expected to increase the clinical significance of these fractures. It was found that salivary cortisol 838 
levels at 2000 hrs were associated with the presence of vertebral fractures and that this relationship 839 
was independent of age and BMD. A negative linear association between 2000 hrs salivary cortisol 840 
and TBS values was also observed. Morning salivary cortisol levels were not found to be associated 841 
with fracture prevalence. In multivariable models both evening salivary cortisol levels and TBS scores 842 
independently predicted the presence of a spine fracture. Although methodologically very different 843 
these two studies strongly support the idea that high exposure to endogenous cortisol levels in the 844 
evening and overnight, even within the normal range, is associated with an increased risk of 845 
fracture.  846 
 847 
III.I.IV Bone impact of variation in glucocorticoid receptor expression. 848 
A further possible way in which endogenous glucocorticoid action within bone could be amplified is 849 
an alteration in the sensitivity or number of the glucocorticoid (or mineralocorticoid) receptors 850 
within the cell or an alteration in post-receptor signalling. Several studies have examined the 851 
influence of GR gene (NC3R1) polymorphisms on the sensitivity of bone to glucocorticoids. These 852 
have generally been small and either negative or reported weak and inconsistent associations. 853 
Huizenga et al examined the influence of the N363S polymorphism of the GR gene on various 854 
aspects of glucocorticoid sensitivity and bone composition.163 Heterozygous carriers of this 855 
polymorphism had greater suppression of serum cortisol levels during a 0.25mg overnight DST 856 
implying greater sensitivity at the level of the GR. In terms of bone density there was a non-857 
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significant difference of approximately 0.5 of a Z-score at the spine (p=0.08) but no suggestion of a 858 
difference at the hip. This study was additionally limited by the low number of people with the 859 
N363S polymorphism at just 10 compared to over 100 controls without. The gene for the GR has not 860 
been linked to osteoporosis or fracture risk in genome wide association studies suggesting that 861 
variation in the GR is unlikely to be a major factor in the development of these conditions. A possible 862 
reason for this lack of association is that relatively modest changes in GR sensitivity are unlikely to 863 
have consequences as long as normal HPA negative feedback is intact. Any difference in sensitivity 864 
would be expected to be compensated for by small changes in circulating levels of cortisol. 865 
GR gene variants that influence glucocorticoid sensitivity could influence the degree of bone damage 866 
that occurs in people with excessive adrenal cortisol production due to disease states or exogenous 867 
glucocorticoid usage. In these situations the HPA negative feedback would be unable to adjust for 868 
difference in glucocorticoid sensitivity. Studies in these situations have suggested a possible impact 869 
of GR variants. Szappanos et al. examined several GR gene variants (N363S, Bcll, ER22/23EK and 870 
A3669G) in 60 people with endogenous Cushing’s syndrome and 129 healthy controls.164 They found 871 
that individuals with Cushing’s syndrome that were homozygous for the Bcll polymorphism had 872 
reduced BMD at the hip by DXA and an increased level of serum betaCTx (a bone resorption marker). 873 
The other polymorphisms did not appear to influence bone. Koetz et al. examined the influence of 874 
the Bcll polymorphism in 112 patients with adrenal insufficiency.165 Patients homozygous for the G 875 
variant (which would be expected to increase cellular glucocorticoid sensitivity) were found to have 876 
greater serum betaCTx and greater urinary NTx. However there was no difference in BMD at hip or 877 
spine. Interestingly these patients were treated with significantly lower doses of replacement 878 
glucocorticoids. This lower dose may have offset the increased tissue glucocorticoid sensitivity.  879 
It might also be hypothesised that variants in GR sensitivity would predict the effects of therapeutic 880 
glucocorticoids on bone. However, these studies are likely to be complicated by any impact that 881 
variation in GR sensitivity might have on the activity of the underlying disease being treated. For 882 
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example, carriers of the N363S or Bcll minor variants (which predict increased glucocorticoid 883 
sensitivity) are reported to have a lower risk of developing rheumatoid arthritis.166 Likewise, patients 884 
with rheumatoid arthritis that are carriers of the Bcll or N363S variants have lower levels of baseline 885 
disease activity even in the absence of glucocorticoid treatment.167 It seems likely that any 886 
differences in GR sensitivity through genetic polymorphism will alter bone sensitivity in parallel to 887 
that of the underlying disease requiring treatment. 888 
 889 
Another mechanism by which glucocorticoid action could be altered at a tissue level is through the 890 
active transport of glucocorticoids across cell membranes. Several membrane transporters can 891 
remove certain types of glucocorticoids from the cytoplasm. This is best exemplified by the active 892 
transport of the synthetic glucocorticoid dexamethasone by cells of the blood brain barrier.168 More 893 
recently the selective transport out of certain tissues of cortisol and corticosterone by ABC 894 
transporters has been highlighted.9 The clinical relevance of these effects is yet to be fully 895 
established and they have not yet been examined in the context of bone cells or GIOP. 896 
 897 
III.II Tissue specific amplification of glucocorticoid action 898 
Traditionally glucocorticoid action at a tissue level has been assumed to be closely linked with the 899 
levels of glucocorticoids in the circulation. More recently it has become apparent that there are 900 
additional potential levels of regulation between the circulation and action at a tissue level. The 901 
most extensively examined of these levels is that of tissue ‘pre-receptor’ glucocorticoid metabolism. 902 
Various enzymes capable of glucocorticoid metabolism are present within bone. The enzymes that 903 
have previously been examined include the 11β-HSDs and 5α-reductases. Although expression of 904 
the 5a-reductase type 1 enzyme has been reported169 the activity of this enzyme in human bone 905 
appears modest and more attention has focussed on the 11β-HSDs.10,170 There are two 11β-HSD 906 
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enzymes. 11β-HSD1 is an intrinsically bidirectional enzyme which interconverts hormonally inactive 907 
cortisone (human) and dehydrocorticosterone (DHC) (rodent) with their active counterparts cortisol 908 
and corticosterone respectively.10 Although bidirectional in most situations in vivo the enzyme acts 909 
principally as an activating enzyme due to the presence of a cofactor generating enzyme hexose-6-910 
phosphate dehydrogenase.171 This enzyme provides a supply of NADPH within the endoplasmic 911 
reticulum where 11β-HSD1 is located. 11β-HSD2 by contrast is a powerful glucocorticoid inactivating 912 
enzyme converting active cortisol and corticosterone to inactive cortisone and DHC. 11β-HSD2 is 913 
normally expressed in classical mineralocorticoid sensitive tissues such as kidney, colon and 914 
pancreas, where it protects the MR from binding by glucocorticoids, whilst 11β-HSD1 is more widely 915 
expressed in tissues such as liver, adipose and skin. In terms of expression within bone, 11β-HSD 916 
activity was first recognised in cultured osteosarcoma cells and primary cultures of osteoblasts.172,173 917 
In osteosarcoma cells 11β-HSD2 mRNA and activity were detected whereas primary cultures of bone 918 
demonstrated exclusive expression of 11β-HSD1173. It is now known that 11β-HSD2 is expressed in a 919 
range of malignant tissues and its presence in osteosarcoma cells is thought to reflect their 920 
malignant status rather than being a feature of bone cells.60,174 Studies in adult mouse and human 921 
bone demonstrate expression of 11β-HSD1 but not 11β-HSD2.59,175 Immunohistochemistry and in 922 
situ hybridisation studies demonstrated that the main cell type expressing 11β-HSD1 in bone were 923 
osteoblasts and osteocytes175. 11β-HSD1 expression was seen to a lesser degree in osteoclasts.175 In 924 
vitro expression appeared to vary across osteoblast differentiation with levels being low in immature 925 
cells, rising and reaching a peak in mature osteoblasts.176 The functional significance of 11β-HSD 926 
expression in bone cells was examined by transfection and stable expression of these enzymes in 927 
osteosarcoma cell lines which do not normally have 11β-HSD activity.177 Whereas empty vector cells 928 
were unresponsive to cortisone, expression of 11β-HSD1 rendered cells sensitive to cortisone in 929 
terms of reduced proliferation and expression of glucocorticoid responsive bone cell markers.  930 
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The expression and activity of 11β-HSD1 have been shown to be regulated by age, cell 931 
differentiation status, inflammation and by glucocorticoids themselves. Primary cultures of human 932 
osteoblasts demonstrated greater ability to generate cortisol from cortisone when cells were grown 933 
from older compared to younger donors.178 This relationship was also observed in mice where mRNA 934 
for 11β-HSD1 was increased in bones obtained from old compared to young mice.77 The 935 
inflammatory cytokines TNFα and IL-1β are powerful stimulators of 11β-HSD1 activity in 936 
mesenchymal derived cell populations such as osteoblasts, and have been proposed as potential 937 
mediators of increased 11β-HSD1 activity in aging.179,180 This upregulation appears to be via an NF-κB 938 
dependent mechanism, although CCAAT/enhancer-binding protein (C/EBP) β has also been shown to 939 
play a role in this inflammatory induction of 11β-HSD1.180-182 Glucocorticoids themselves also cause a 940 
modest increase in 11β-HSD1 activity and expression in osteoblasts and they can synergise with pro-941 
inflammatory cytokines to cause a more dramatic increase in 11β-HSD1 expression.178,183.  942 
Clinical studies also indicate the presence of 11β-HSD1 within bone. In a cohort of elderly subjects 943 
the level of cortisone in the circulation was a significant negative predictor of the blood level of 944 
osteocalcin whereas cortisol was not.159 This suggested that 11β-HSD1 within osteoblasts is a 945 
regulator of osteocalcin synthesis. A number of relatively small genetic association studies have 946 
suggested that polymorphisms in the 11β-HSD1 gene (HSD11B1) might contribute to the 947 
development of osteoporosis, regulate the level of serum osteocalcin, or increase the risk of 948 
fracture.184-187 However, the gene has not been identified as a candidate in large GWAS studies. It is 949 
possible that these polymorphisms might be important in some ethnic groups but not others. It also 950 
needs to be considered that 11β-HSD1 is also expressed in other tissues and any associations could 951 
be mediated indirectly e.g. through an effect on the regulation of the degree of inflammation, rather 952 
through an effect on bone cells themselves.  953 
The functional role of 11β-HSD1 in bone has been examined in some animal models. In mice with 954 
global deletion of 11β-HSD1 there is no alteration in bone density or structure.188 However, on the 955 
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background examined the 11β-HSD1 global knock out mice have an alteration in feedback regulation 956 
of the HPA axis leading to a high level of corticosterone in the circulation.189 It is possible that this 957 
high circulating level might offset any tissue level reduction in glucocorticoid levels. The global 958 
knockout mouse has not been evaluated in the context of old age or in models of glucocorticoid 959 
excess and inflammation associated osteoporosis. Certainly, in the context of glucocorticoid induced 960 
muscle wasting, skin thinning and hepatic steatosis, global deletion of 11β-HSD1 results in almost 961 
complete protection raising the possibility that these mice will also be protected from glucocorticoid 962 
induced osteoporosis.  963 
The 11β-HSD enzymes also regulate the activity of the most widely used oral glucocorticoids 964 
prednisone and prednisolone.190 11β-HSD1 converts inactive prednisone to active prednisolone with 965 
similar enzyme kinetics to that of the conversion of cortisone to cortisol. In healthy males the 966 
baseline level of 11β-HSD1 (measured as the ratio of corticosteroid metabolites on a 24 hour urine 967 
collection) predicted the response of bone formation markers to a short course (7 days) of oral 968 
prednisolone. High baseline 11β-HSD1 activity was associated with the greatest falls in serum 969 
osteocalcin and PINP levels. This relationship was independent of the circulating levels of prednisone 970 
or prednisolone. The conclusions from this study are limited due to the activity being measured in 971 
the total body rather than in the bone itself. Additionally, even though the predictive ability of total 972 
measures of 11β-HSD1 activity are predictive of the response of bone to glucocorticoids these 973 
relationships may not persist in patients treated with glucocorticoids for inflammatory disease since 974 
inflammation itself is associated with a tissue specific increase in 11β-HSD1 activity.191 In patients 975 
with inflammatory bowel disease baseline measures of 11β-HSD1 activity on a urine sample were 976 
not predictive of the change in bone density in response to oral glucocorticoid treatment.192  977 
Given that inflammation increases 11β-HSD1 activity and activation of therapeutic glucocorticoids 978 
within bone cells, the potential exists for locally activated steroids to both abrogate inflammatory 979 
bone loss whilst directly contributing to glucocorticoid mediated bone loss. Clinical data suggest that 980 
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the reality may lie somewhere in-between the two, with therapeutic glucocorticoids partially 981 
suppressing disease activity in patients with chronic inflammatory disease and reducing immediate 982 
bone loss whilst ultimately contributing to glucocorticoid-induced osteoporosis with prolonged 983 
use.193,194 These data support the idea that a rapid and marked increase in 11β-HSD1 in response to 984 
inflammation is an important part of the host response to inflammation, with elevated 985 
glucocorticoid activation preventing inflammatory bone loss in an acute setting. This situation is 986 
complicated in chronic inflammation, where prolonged increases in 11β-HSD1 may begin to promote 987 
bone loss in a similar fashion as seen with long term therapeutic glucocorticoid application.  988 
If correct, the targeted inhibition of 11β-HSD1 in an inflammatory context may be highly 989 
disadvantageous, in a similar manner as reported in the muscles of mice with systemic inflammation 990 
on a 11β-HSD1 KO background.195 Here, the reduction in local steroid activation within muscle 991 
greatly increases systemic inflammation and local muscle inflammatory cytokine production, 992 
increasing inflammatory catabolic and anti-anabolic muscle wasting. In a similar manner, systemic 993 
inhibition of 11β-HSD1 may exacerbate inflammatory bone loss. Instead, alternative approaches, for 994 
example, targeted inhibition of pro-inflammatory NF-κB (or any other tissue specific regulator of 995 
11β-HSD1 activity) or bone selective inhibition of 11β-HSD1 may be a more effective approach.  996 
 997 
IV Therapeutic glucocorticoid excess and bone 998 
This section reviews data relating to the epidemiology and treatment of iatrogenic GIOP. 999 
Importantly, as discussed throughout this article, the term GIOP in this context could be misleading. 1000 
This is because therapeutic glucocorticoids might indeed lead to bone loss through their direct 1001 
actions but are also likely to have complex interactions with the underlying disease being treated.5,6 1002 
Glucocorticoids in some situations might magnify the amount of damage being done to bone 1003 
through worsening of imbalances between bone formation and resorption but in conditions 1004 
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characterised by systemic inflammation, glucocorticoids, particularly when used at modest doses 1005 
might be ‘bone sparing’ through their anti-inflammatory actions.196,197 In the later situation bone 1006 
disease might be present in the context of prolonged glucocorticoid use but the damage would not 1007 
be truly ‘glucocorticoid-induced’. It is generally thought that most systemic inflammatory illnesses 1008 
cause bone loss primarily through increased bone resorption with a relative suppression or restraint 1009 
on bone formation.6,198 The effectiveness of different treatment approaches (anti-resorptive agents 1010 
targeting osteoclast activity vs. anabolic drugs targeting bone formation) might depend on the 1011 
extent to which bone disease is secondary to inflammation or to the glucocorticoids needed to 1012 
control the underlying disease.  1013 
IV.I Epidemiology of glucocorticoid use and impact on bone 1014 
The use of therapeutic glucocorticoids in the community is still high and may even be increasing. 1015 
Studies around the turn of the century from the UK reported that up to 1% of the population were 1016 
taking oral glucocorticoids on a long term basis.199,200 This figure rose to almost 3% in the elderly. 1017 
Data from the US based on the NHANES database between 1999 and 2008 estimated that the 1018 
prevalence of long term use was 1.2%.201 In the Global Longitudinal Study of Osteoporosis in Women 1019 
(GLOW) the rate of glucocorticoid usage at baseline study visit in this post-menopausal population 1020 
was 4.6%.202 Studies based on UK databases indicate that the rate of long term glucocorticoid use is 1021 
gradually increasing.203 A recent study based on the population of Denmark reported that 3% of the 1022 
Danish population filled at least one prescription for a systemically administered therapeutic 1023 
glucocorticoid. In the Danish elderly population this figure rose to around 8-10%.204 As such a 1024 
significant proportion of the global population is exposed to therapeutic glucocorticoids.  1025 
Several studies have attempted to estimate the fracture risk associated with long term 1026 
glucocorticoid use. In some groups of patients treated long-term with oral glucocorticoids, the risk of 1027 
developing osteoporosis and vertebral fractures was estimated at 50% or more.4 These rates will 1028 
depend on the specific disease being treated and the age and gender profile of the populations 1029 
44 
 
studied. Population based studies have similarly indicated that glucocorticoid usage is associated 1030 
with an increased risk of fracture.3 Importantly, risks of fracture were increased at the hip (relative 1031 
risk increase 1.6) and spine (relative risk increase 2.6) as well as an increased risk of non-vertebral 1032 
fractures (relative risk 1.3). Even relatively modest doses of glucocorticoids were associated with a 1033 
significantly increased fracture risk, with doses as low as 2.5mg/day being linked to spine fractures. 1034 
Risk of fractures was also associated with daily dose with a 20% increased risk of fracture seen at 5 1035 
mg/day of prednisolone, increasing to 60% at 20 mg/day. The time of onset and offset of fracture 1036 
risk was particularly instructive. In the study by van Staa et al. the risk of fracture increased rapidly 1037 
within a short time of commencing glucocorticoid therapy.3 The risk of fracture remained elevated 1038 
while glucocorticoids were continued but fell rapidly after glucocorticoids were ceased. The 1039 
mechanisms for these rapid changes in fracture risk are unclear but changes in bone density alone 1040 
are an unlikely explanation. An increased risk of falls due to myopathy associated with glucocorticoid 1041 
use might be part of the explanation. The risk of fracture also appeared to increase in glucocorticoid 1042 
users even before therapy was initiated, indicating that the indication for treatment is an important 1043 
component of the increase in risk of fracture during therapy. As such glucocorticoid treatment is 1044 
likely to be a marker of the presence of a disease associated with increased fracture risk as well as an 1045 
independent factor itself. Support for this involvement of underlying disease in fracture risk comes 1046 
from studies of patients taking inhaled glucocorticoids for respiratory disease, who had a higher 1047 
fracture risk than healthy matched controls.205  However, patients taking inhaled bronchodilators but 1048 
no inhaled glucocorticoids had a similar increase in fracture risk compared to controls, a finding that 1049 
implies that the underlying respiratory condition was the most significant contributor to fracture 1050 
risk.  1051 
Subsequent studies have attempted to determine whether fracture risk was associated with 1052 
cumulative or daily dose. In general both dose and duration influence fracture risk and these two 1053 
factors are difficult to separate out in clinical practice.206,207 The question was recently addressed in a 1054 
population based cohort of over 50,000 patients from Canada which examined the relative 1055 
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importance of recent or remote and short or prolonged use of glucocorticoids on bone density and 1056 
fracture incidence.208 In this cohort only recent prolonged glucocorticoid use was associated with 1057 
reduced femoral neck T-scores and a BMD-independent increase in the risk of major and hip 1058 
fractures. However, most other studies provide reassurance that glucocorticoid use is only harmful 1059 
to bone when used for relatively long durations. Occasional intermittent use of high dose 1060 
glucocorticoids has been reported to be relatively safe in terms of bone health.209 However, a recent 1061 
retrospective cohort study based on private insurance claims from the US demonstrated an 1062 
association between short-term glucocorticoid use (less than 30 days) with various types of harm 1063 
including a 1.8 fold increased risk of fracture.210 Such short-term use of glucocorticoids was common 1064 
at 20% of the population over the 3-year period examined, suggesting that intermittent 1065 
glucocorticoid use could contribute more to population fracture risk than previously thought. 1066 
Another important source of information relating to the epidemiology of GIOP are the placebo arms 1067 
of the initial RCTs that examined the impact of various treatments on the development of GIOP.211-1068 
213 This approach has the advantage of having greater sensitivity for determining the impact of 1069 
glucocorticoids on vertebral fracture risk as spine radiographs were typically taken in these trials. 1070 
Overall, the placebo arms of these studies indicate that glucocorticoid treatment is associated with a 1071 
high risk of fracture, particularly vertebral fracture in post-menopausal women and older men.101,214 1072 
However, the risk of fracture in pre-menopausal women and younger men appeared to be very low. 1073 
Where fractures did occur the BMD T-score tended to be below a level of -1.5. Whether these 1074 
younger patient groups have reduced absolute risks of fracture by virtue just of their age or whether 1075 
there are independent age related protective factors such as sex steroid levels remains unclear. A 1076 
recent formal meta-regression of data from the placebo arms of these studies has reported annual 1077 
incidence rates of vertebral fracture of 5.1% and 3.2% for patients initiating or continuing 1078 
glucocorticoid treatment respectively.214 The corresponding rates of non-vertebral fractures were 1079 
2.5% and 3.0%. 1080 
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Other studies have attempted to define the effect of glucocorticoid treatment on bone density and 1081 
architecture over time. Zhu et al. performed a carefully controlled prospective study of women with 1082 
SLE on long term glucocorticoids followed up for over 2 years.215 Areal BMD by DXA at multiple sites 1083 
and microstructural analysis by high resolution peripheral QCT (HR-pQCT) at the distal radius were 1084 
examined at baseline, 12 and 24 months. In premenopausal women the changes in aBMD by DXA 1085 
over the two years were very similar between cases and controls. There was however a significant 1086 
decrease in cortical area and thickness and an increase in cortical porosity in cases compared to 1087 
controls. In post-menopausal women, again there was no significant difference in changes in BMD 1088 
between cases and controls but by HR-pQCT there was a significant decrease in volumetric BMD at 1089 
the cortex and more substantial decreases in cortical thickness and increases in cortical porosity. The 1090 
increases in porosity seen were double in post-menopausal women compared to premenopausal 1091 
women and the decrease in cortical thickness 10 fold greater. As such, at least in SLE, cortisol bone 1092 
loss is significant during glucocorticoid treatment with the magnitude of changes being substantially 1093 
greater in post-menopausal women. This data indicate that prolonged use of glucocorticoids leads to 1094 
deterioration in bone, and in particular cortical architecture, even in the absence of any changes in 1095 
BMD measured by DXA. A similar DXA independent deterioration in bone quality may also occur at 1096 
the spine. Paggiosi et al. compared spine aBMD by DXA and TBS values in 484 women treated with 1097 
or without glucocorticoids.216 There was no difference in aBMD between groups but the TBS Z-score 1098 
was 0.8 lower in the group treated with glucocorticoids. Whether the change in TBS is predictive of 1099 
fractures in this situation is not yet clear. 1100 
An important consideration in these studies is whether the changes in trabecular or cortical bone 1101 
seen in people treated with glucocorticoids is due to the glucocorticoids or to the underlying disease 1102 
being treated. Some studies suggest that the underlying disease itself could be contributing more to 1103 
the adverse effects on bone than glucocorticoids. For example Olsson et al. examined the effect of 1104 
short term, high dose glucocorticoids on bone in patients with multiple sclerosis.217 No independent 1105 
association was found between glucocorticoid usage and BMD. However, disease activity was 1106 
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strongly associated with decreases in spine and hip BMD. In a population based cohort study 1107 
examining 1 million patients with or without COPD, COPD severity was strongly related to an 1108 
increased risk of osteoporosis and fracture.218 However, prednisolone use and inhaled corticosteroid 1109 
use were associated with a reduced rather than increased risk of osteoporosis. Although this type of 1110 
study could be influenced by confounding this is further evidence of the importance of the 1111 
underlying disease on fracture risk in glucocorticoid treated patients. Even though reductions in 1112 
BMD in patients treated with glucocorticoids may be more strongly related to the underlying disease 1113 
in some circumstances than the glucocorticoids themselves, from a practical point of view BMD 1114 
measurements are still clinically useful as these patients are likely to be at an increased risk of 1115 
fracture and likely to benefit from treatment. 1116 
 1117 
IV.II Risk stratification in the clinical setting 1118 
As with guidelines relating to other forms of osteoporosis there has been a shift away from fixed cut 1119 
off values of BMD by DXA as the basis for estimation of risk to the use of calculators such as FRAXTM 1120 
219and the Garvan Fracture Risk calculator220 that include multiple aspects of fracture risk. Currently 1121 
guidelines for GIOP risk stratification attempt to focus on estimated absolute risk but usually include 1122 
additional ‘red flags’ that would prompt treatment even if the estimated risk is below the 1123 
intervention threshold. A question relating to exposure to glucocorticoids is incorporated into 1124 
FRAXTM, the most widely used fracture risk calculator, but not other fracture risk calculators. The 1125 
glucocorticoid question requires a yes/no answer with the yes answer indicated if the patient is 1126 
currently exposed to oral glucocorticoids or has been exposed to oral glucocorticoids for more than 1127 
3 months at a dose of prednisolone of 5mg daily or more. As discussed earlier, the risks associated 1128 
with glucocorticoids in epidemiological surveys indicate that current treatment with glucocorticoids 1129 
is a more powerful risk factor for fracture than remote use and the relationship is also, to some 1130 
extent, dose dependent. To address this additional guidance is now available on how to adjust the 1131 
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FRAX output manually based on glucocorticoid dose and recency of exposure.219 A more 1132 
fundamental limitation of FRAX and other calculators in the context of GIOP is the focus on hip and 1133 
non-vertebral fractures with little emphasis on spine fractures. This extends to the requirement to 1134 
enter femoral neck BMD with no possibility of entering spine BMD scores. As such in younger 1135 
patients with relatively preserved BMD it is unlikely that high fracture risk values will be generated 1136 
even if the risk of spine fractures was clinically significant. To address this, many guidelines also 1137 
suggest treatment to be considered if the patient has a low traumatic fracture, or has a low BMD e.g. 1138 
less than -1.5 T score by DXA, particularly at the spine. Although not evaluated in the context of 1139 
clinical studies it would seem reasonable clinical practice to have a lower threshold for obtaining 1140 
spine radiographs or VFA by DXA (if available) in patients at risk of GIOP. 1141 
 1142 
IV.III Treatment strategies  1143 
There are a range of guidelines and recommendations published for the pharmacological treatment 1144 
of GIOP.221-223 Intervention thresholds and rules for treatment use and patient reimbursement vary 1145 
considerably between countries. These guidelines will not be reviewed extensively here but rather 1146 
the evidence related to the effectiveness of various treatments specifically on fracture risk are 1147 
described below.  1148 
A number of RCTs have been performed in the context of GIOP. These are generally much smaller in 1149 
size than the RCTs that demonstrated the effectiveness of these medications in post-menopausal 1150 
osteoporosis and generally were not powered for fracture. The main RCTs that compared 1151 
treatments to placebo include those that evaluated etidronate,212 alendronate213 and risedronate,211 1152 
whereas zoledronic acid224 and teriparatide225 evaluated medications in non-inferiority studies. 1153 
These trials consistently demonstrated improvements in BMD by DXA relative to placebo in patients 1154 
treated shortly after initiation of glucocorticoids and patients treated with glucocorticoids prior to 1155 
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initiation of therapy. Although not powered for fracture risk reduction, post-hoc analyses have 1156 
indicated the likely impact of these treatments on fracture risk, particularly at the spine.226,227 Other 1157 
studies have examined the effect of vitamin D or its metabolites but these have generally been 1158 
smaller and found less substantial changes in BMD.228-230 Due to heterogeneity of inclusion criteria, 1159 
baseline fracture risk and methods of ascertainment of BMD and fracture incidence it is difficult to 1160 
compare between treatments. However, the effectiveness of aldendronate and teriparatide has 1161 
been compared in the context of non-inferiority. Saag et al. compared teriparatide with alendronate 1162 
treatment over 18 months in a randomised double blind study of 428 women and men receiving 1163 
therapeutic glucocorticoids.225 Spine BMD by DXA increased substantially more in the teriparatide 1164 
group than in the alendronate group. Most importantly, in a pre-specified secondary analysis, the 1165 
risk of developing new morphometric vertebral fractures were considerably lower in patients taking 1166 
teripartide (0.6%) than alendronate (6.1%). These results are dramatic especially taking into account 1167 
that alendronate substantially reduces the risk of new morphometric vertebral fractures when 1168 
compared to placebo.226 The superiority of teriparatide compared to bisphosphonates for increasing 1169 
bone strength at the spine is also supported by an open label randomised trial of teriparatide versus 1170 
and risedronate in men treated with glucocorticoids.231 This smaller RCT (92 men in total) focussed 1171 
primarily on spine BMD and structural parameters using DXA, QCT of L1-3, and high resolution QCT 1172 
or the T12 vertebra. Both treatments led to improvements in various parameters of bone density 1173 
and strength but these were in general much greater with teriparatide. Estimates of vertebral 1174 
strength using finite element analysis (FEA) demonstrated clear superiority of teriparatide over 1175 
risedronate. Even though small, there was also a trend towards fewer spine fractures in men treated 1176 
with teriparatide compared to those treated with risedronate. The effects of alendronate versus 1177 
teriparatide on spine TBS have also been compared in a secondary analysis of a RCT of these 1178 
treatments in GIOP.232 It was found that alendronate had no impact on TBS despite increasing aBMD 1179 
whereas teriparatide caused a significant increase in TBS in addition to positive impact on aBMD. 1180 
These data collectively indicate that the bisphosphonates and teriparatide are effective in reducing 1181 
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fracture risk at the spine in GIOP but teriparatide appears superior over 18 months. An important 1182 
caveat regarding teriparatide is that it is generally only licenced for a duration of 18 months 1183 
(depending on country) and subsequent anti-resorptive medications are typically needed after this 1184 
treatment ends.  1185 
The small size of these RCTs and relative rarity of non-vertebral and hip fractures compared to 1186 
morphometric spine fractures means that the effect of these drugs on non-vertebral and hip fracture 1187 
risk is not possible to determine. Three recent publications have used retrospective database 1188 
analysis to try to determine the real world impact of these medications on overall fracture risk and 1189 
hip fracture risk specifically. Overman et al. examined the effect of anti-osteoporotic medications 1190 
(AOMs, including bisphosphonates, teriparatide and denosumab) collectively on the risk of clinical 1191 
fractures in women aged 50 plus taking oral glucocorticoids included in the MarketScan databases. 1192 
The analysis included 7885 women with 12.1% of them treated with AOMs. It was found that AOM 1193 
use was associated with significantly reduced hazard ratios (HRs) for fracture of 0.52 at 1 year and 1194 
0.68 at 3 years.233 Axelsson et al. examined the association between alendronate use and hip 1195 
fracture risk in women and men using glucocorticoids in a national Swedish database including 1196 
433,195 patients 65 years and older.234 The use of alendronate was associated with a significantly 1197 
reduced risk of hip fracture (HR 0.35). A third study by Bergman et al. also used Swedish national 1198 
databases which included over 3 million people to compare the impact of alendronate on risk of 1199 
fracture in patients treated with glucocorticoids.235 They found that alendronate use was associated 1200 
with a 16% reduction in non-vertebral fracture and a 34% reduction in hip fractures compared to 1201 
non-users. These studies clearly have intrinsic limitations due to their non-randomised nature and 1202 
could be influenced by confounding by indication. However, sensitivity analyses within these studies 1203 
consistently supported a strong and clinically important reduction in non-vertebral and hip fracture 1204 
risk in patients taking glucocorticoids who are treated with anti-osteoporosis medications. 1205 
Importantly, these studies also failed to detect any evidence of harm relating to gastrointestinal 1206 
adverse reactions with these medications. These reductions in non-vertebral fracture risk imply that 1207 
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treatments for GIOP might also improve the strength of cortical bone. A recent study directly 1208 
examined in vivo changes in bone tissue properties in glucocorticoid treated patients commencing 1209 
various osteoporosis treatments.236 Reference point indentation (a form of microindentation) was 1210 
performed on the tibia using a hand held device under local anaesthetic. This technique measures 1211 
the resistance of cortical bone to indentation and thus provides a measure of tissue properties. Over 1212 
periods of 7 and 20 weeks treatment with calcium and vitamin had no impact on material properties 1213 
(the Bone Material Strength Index; BMSi). However, treatment with risedronate over 20 weeks and 1214 
treatment with denosumab or teriparatide over 7 and 20 weeks resulted in a significant increase in 1215 
BMSi. There was however no change in BMD by DXA in any group. Although the clinical utility of 1216 
microindentation techniques remains uncertain these preliminary studies strongly support a rapid 1217 
and beneficial effect of osteoporosis medications on cortical bone properties in patients at risk of 1218 
GIOP. 1219 
A concern with anti-resorptive drugs is that they predispose to the development of atypical femoral 1220 
fractures (AFFs). Although the pathogenesis of AFFs is still unclear decreased bone turnover is 1221 
implicated. Since both anti-resorptive medications and glucocorticoids decrease bone turnover 1222 
prolonged use of both might theoretically increase the risk of AFFs. Although early reports237 1223 
suggested a possible link between glucocorticoids and AFFs in patients taking bisphosphonates more 1224 
recent studies do not support such an association.238 1225 
A 2 year double blind placebo controlled non-inferiority RCT examining the effectiveness of 1226 
denosumab compared to risedronate in over 700 women and men with GIOP has been completed 1227 
but not published. Data from the 1st year of treatment has been reported in abstract form and the 1228 
drug appears to have a positive effect on bone mineral density with increases at spine and hip in 1229 
excess of those seen with risedronate. Small observational studies of the use of denosumab in GIOP 1230 
suggest that the drug is effective in maintaining or increasing BMD.239-241 Formal licencing of 1231 
denosumab for this indication is expected in the future. 1232 
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 1233 
V Skeletal impact of glucocorticoid replacement 1234 
This section will review the data relating to the skeletal impact of glucocorticoid replacement for 1235 
primary or secondary adrenal insufficiency. The amount of literature in this area is modest but there 1236 
have been some recent contributions and the subject is clearly of relevance to an endocrine 1237 
audience. When interpreting the literature relating to the impact of glucocorticoid replacement on 1238 
bone it is important to consider that patients are treated for long periods of time with some patients 1239 
treated for several decades, that treatment regimens have varied over time with a trend to using 1240 
lower doses of glucocorticoids in more recent years, and that glucocorticoid replacement may be 1241 
only one aspect of their underlying condition that might impact on bone. For example, patients 1242 
treated for Addison’s disease will additionally have adrenal androgen deficiency and a greater 1243 
chance of previous thyrotoxicosis; patients with hypopituitarism will commonly have coexisting 1244 
growth hormone deficiency and patients with CAH will commonly have differences in height and 1245 
bone structure that make comparisons to controls difficult. Much of the literature focusses on BMD 1246 
by DXA but there is some fracture risk data. 1247 
The epidemiology of hip fractures in patients with Addison’s disease has been examined in a 1248 
population based analysis from Sweden.242 Using hospital database, information relating to the 1249 
diagnosis of autoimmune adrenal insufficiency and hip fracture of 3,219 patients were identified and 1250 
compared to over 31,000 age and sex matched controls from the background population. The risk of 1251 
hip fracture was found to be substantially increased with a hazard ratio of 1.8 (CI 1.6-2.1). The 1252 
relative risk increase was independent of age or sex. The risk of any fracture was also increased to a 1253 
similar degree. The relationship between risk of hip fracture and the time of diagnosis of Addison’s 1254 
disease was also explored. The relative risk of fracture was most increased in the first year after the 1255 
diagnosis but was elevated at all time points. Interestingly, the risk of fracture was also increased by 1256 
almost 3-fold in the year prior to the diagnosis, indicating that the cause of the increased fracture 1257 
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incidence, at least at this time point is not glucocorticoid replacement. It is possible that 1258 
glucocorticoid deficiency has a major negative effect on bone in keeping with some of the 1259 
observations of an anabolic effect of physiological levels of glucocorticoid action within bone.50,63,66 1260 
However, there are additionally many other reasons for this increased fracture risk not least an 1261 
increased risk of falls arising from the often severe myopathy seen in untreated adrenal failure.243 1262 
Nevertheless the data support the notion that fracture risk might be increased in patients that are 1263 
undertreated as well as those that are over-treated with replacement glucocorticoids. 1264 
Other studies have focussed on bone density in Addison’s disease. These were mostly cross-sectional 1265 
and are difficult to interpret since some of the patients included had been exposed to higher doses 1266 
of glucocorticoids than typically used now for prolonged periods of time. In general these studies 1267 
reported that adrenal insufficiency was associated with a reduction in BMD at the spine and the hip 1268 
and that this reduction was greater with more prolonged use. These studies are summarised in a 1269 
recent review by Lee and Greenfield.244 One relatively recent cross-sectional study of patients with 1270 
Addison’s disease or CAH treated with lower glucocorticoid replacement doses failed to find a 1271 
reduction in BMD as assessed by DXA suggesting that replacement regimens adopted more recently 1272 
have less negative impact on bone.245 However, another study of 87 patients with Addison’s disease 1273 
and 81 age and sex matched controls found a higher than expected prevalence of spine fractures 1274 
(using DXA based vertebral fracture assessment (VFA)) in patients with adrenal insufficiency despite 1275 
there being no difference in BMD.246 Using the Genant criteria 31% of Addison’s patients had at least 1276 
one vertebral abnormality compared to 12.8% of controls. Suggesting that these fractures might be 1277 
related to treatment the risk of fracture appeared greater in those with a longer duration of disease. 1278 
Interestingly mineralocorticoid replacement was associated with the presence of a higher BMD.  1279 
A recent prospective study examined the impact of targeted reduction in glucocorticoid replacement 1280 
dose in patients with Addison’s disease and CAH.247 In patients where a reduction in glucocorticoid 1281 
replacement appeared justified there was a significant increase in spine and hip Z scores over a 2 1282 
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year follow up period. This suggests that bone health can be improved by careful attention to 1283 
glucocorticoid replacement doses but the actual impact of these changes on risk of fractures has not 1284 
been examined.  1285 
Several studies have examined the bone health of individuals with CAH and the likely impact of 1286 
glucocorticoid replacement.248-252 These studies are complicated by the differences in height and 1287 
bone size, which tend to overstate reductions in BMD. Additionally, excessive androgen exposure 1288 
resulting from inadequate glucocorticoid dosing might have an anabolic effect on bone. However 1289 
despite this it appears that bone density is reduced at all skeletal sites in CAH using both DXA and 1290 
spinal QCT. The reduction has been correlated with cumulative glucocorticoid exposure in some 1291 
studies249 but not others.248 Two small studies by the same research group found that adult women 1292 
with CAH had an increased risk of fracture251 but men with CAH did not.252 1293 
  1294 
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VI Future directions 1295 
Currently it is unclear how to separate the anabolic versus catabolic actions of glucocorticoids on 1296 
bone. Endogenous glucocorticoids have powerful effects on bone health which appear to some 1297 
extent to be regional and surface dependent. In scientific studies there is no consistency in the 1298 
regions and surfaces examined which makes comparisons between studies difficult.  1299 
There are also limitations with current animal models as it is unclear to what extent they adequately 1300 
model the human situation. Few examine the sensitivity of bone in the context of an underlying 1301 
illness which is being treated with glucocorticoids. Animal studies examining interventions to protect 1302 
against GIOP need to be assessed in inflammatory disease models to determine whether these 1303 
interventions have independent actions on the underlying illness being treated in the first place. 1304 
It remains unclear if there is a single target for glucocorticoid action within bone that can be 1305 
targeted therapeutically. Although there have been attractive targets such as the IGF1 system, 1306 
osteoblast apoptosis, IL-11, autophagy, OPG/RANKL and wnts/DKK1/sclerostin no single system 1307 
appears to account for all of the actions of glucocorticoids on bone. As discussed above, even if a 1308 
single target was identified it would need to be clear that this target was not involved in the 1309 
beneficial effects of glucocorticoids on the immune system. Currently the most likely candidates in 1310 
this respect are approaches that target sclerostin and/or DKK1 (the other major antagonist of wnt 1311 
signalling). The feasibility of such an approach has been demonstrated in principle outside the 1312 
context of glucocorticoid therapy in rodents and non-human primates.253  1313 
It should also be remembered that glucocorticoid excess is associated with many adverse effects 1314 
outside of bone and these are currently not addressed well. An ideal treatment approach would 1315 
target multiple components of risk. Being able to do this without blocking the anti-inflammatory 1316 
actions of glucocorticoids has proven difficult. One approach to achieve this goal that has been an 1317 
active topic of research for several decades is the development of selective glucocorticoid receptor 1318 
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modulators. There are various theoretical underpinnings of these molecules largely based on the 1319 
concept of dissociating effects of glucocorticoids which are mediated by transactivation and 1320 
transrepression.254,255 These concepts now appear overly simplistic and furthermore the actions of 1321 
glucocorticoids on bone appear to be through transrepression rather than transactivation.50 There 1322 
have been some interesting compounds examined, in particular ‘compound A’, which exhibits some 1323 
useful features although it’s relatively narrow therapeutic range is likely to limit human use.256 Also, 1324 
these agents are complicated by the likelihood that they could interfere with HPA axis regulation 1325 
leading to low levels of endogenous cortisol. This could create a mixture of excessive glucocorticoid 1326 
action in some tissues but an absence of glucocorticoid action in others. Moreover, these 1327 
compounds would not exhibit the same properties of selective activation by tissue specific enzymes 1328 
and would be unlikely to have effects on the MR (which could play a role in some inflammatory 1329 
situations or even modulate the impact of more conventional glucocorticoids on bone). Given these 1330 
complexities selective glucocorticoid receptor modulators are unlikely to be developed but if they 1331 
are they would probably need to be evaluated in specific inflammatory conditions rather than for 1332 
inflammatory disease in general. 1333 
There also remains uncertainty regarding what is actually being treated in patients with GIOP. In 1334 
some contexts glucocorticoids are likely to be detrimental but in other situations altered bone 1335 
remodelling due to the underlying inflammatory disease might be more important. Glucocorticoids 1336 
might therefore have an important role in controlling inflammation related bone loss and thus be 1337 
bone ‘sparing’ rather than negative to bone. If this distinction can be made it might be possible to 1338 
independently target glucocorticoid induced and inflammation induced bone disease separately or 1339 
synergistically. 1340 
  1341 
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